Aug 29, 2008

DNI Avian Influenza Daily Digest

UNCLASSIFIED

Intelink Avian Influenza Daily Digest

Avian Influenza Daily Digest

August 29, 2008 14:00 GMT

This digest is produced by the United States Government, Office of the Director of National Intelligence, Washington DC, USA. Articles and resource documents in this digest are from open sources and unclassified.

This digest contains raw open source content and is not an evaluated intelligence product. Readers are encouraged to contribute updates and/or clarifications that will be posted in subsequent issues of the digest. Articles may contain copyrighted material, further dissemination outside government channels may be prohibited without permission from the copyright owners.

Please note some links may only work while connected to the Intelink network.

Unsubscribe/Subscribe to the AI Digest
Contact AI Digest Editor/Contribute (U) Information
Contribute (U) Updates/Clarifications to a previously reported article
Contribute (U) Information anonymously


Intelink Avian Influenza Resources:
U.S. Govt. IC: Intelink AI/Pandemic page https://www.intelink.gov/mypage/avianflu


Article Summaries ...

Quid Novi

Iraq: Reports of Chicken Die-offs on 70 Farms

Indonesia: Reports of poultry die-off in North Sumatera

Regional Reporting and Surveillance

Panama: Ministry Reserves 200,000 Doses of Tamiflu
8/29/08 ARGUS--A national source reports that the Ministry of Health has reserves of more than 200,000 individual doses of oseltamivir (Tamiflu) in the event of an avian influenza pandemic. In addition, the Gorgas Institute Commemorative will rely on a regional investigative lab to conduct a diagnosis in less than 24 hours. There has not been a case of avian influenza registered in Panama, but Panama is part of the migratory route for millions of birds from North to South America between September and October. The Ministry of Agricultural Development has identified locations where birds nest and feed en route along the Caribbean coast, far from farmlands. More than 7,000 samples of migratory birds have been analyzed; all tested negative for AI.
Regional Reporting and Surveillance

OIE: UK Follow Up #3 (Final Report)
Highly pathogenic avian influenza, United Kingdom Information received on 28/08/2008 from Dr Nigel Gibbens, Chief Veterinary Officer, Department for Environment, Food and Rural Affairs, Department for Environment, Food and Rural Affairs, LONDON, United Kingdom Summary Report type Follow-up report No....
Regional Reporting and Surveillance

VIETNAM: Uphill battle to raise awareness of bird flu
8/29/08 Irin News--The key message that needs to be heard is that Avian Influenza (AI) is endemic in Vietnam and needs to be controlled, say UN officials involved in the battle to identify and contain avian influenza outbreaks.
Regional Reporting and Surveillance

Kurdistan: Poultry production capacity falls
8/28/08 Kurdish Globe--Lack of basic services on poultry farms has, in addition to shutting down many farms, increased cost of production and decreased quantity of production.
Regional Reporting and Surveillance

UK: Bird flu 'will stay in Britain for five years'
8/29/08 Edinburgh News--BIRD flu will arrive in Britain within months and stay for at least five years, the government's chief scientific adviser has predicted.
Regional Reporting and Surveillance

FAO assures Bangladesh of support towards food security
8/29/08 Xinhua--A visiting high official of United Nation's Food and Agriculture Organization (FAO) Friday assured Bangladesh of providing necessary support in its efforts to ensure food security.
Regional Reporting and Surveillance

Australia: The battle to secure our borders against a tiny, but lethal, enemy force
8/28/08 Sydney Morning Herald--We once thought the battle against infectious disease was won. Security experts now tell us this is not so. In a globalised, interconnected world - where people, trade and goods move around like never before - people, their pets, livestock, wildlife and crops are still vulnerable.
Regional Reporting and Surveillance

Science and Technology

Genotypic diversity of H5N1 highly pathogenic avian influenza viruses
8/29/08 Journal of General Virology--[Abstract]--Besides enormous economic losses to the poultry industry, recent H5N1 highly pathogenic avian influenza viruses (HPAIVs) originating in eastern Asia have posed serious threats to public health. Up to April 17, 2008, 381 human cases had been confirmed with a mortality of more than 60 %. Here, we attempt to identify potential progenitor genes for H5N1 HPAIVs since their first recognition in 1996; most were detected in the Eurasian landmass before 1996. Combinations among these progenitor genes generated at least 21 reassortants (named H5N1 progenitor reassortant, H5N1-PR1?21). H5N1-PR1 includes A/Goose/Guangdong/1/1996(H5N1). Only reassortants H5N1-PR2 and H5N1-PR7 were associated with confirmed human cases: H5N1-PR2 in the Hong Kong H5N1 outbreak in 1997 and H5N1-PR7 in laboratory confirmed human cases since 2003. H5N1-PR7 also contains a majority of the H5N1 viruses causing avian influenza outbreaks in birds, including the first wave of genotype Z, Qinghai-like and Fujian-like virus lineages. Among the 21 reassortants identified, 13 are first reported here. This study illustrates evolutionary patterns of H5N1 HPAIVs, which may be useful toward pandemic preparedness as well as avian influenza prevention and control. {dagger}Present address: Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. The GenBank/EMBL/DDBJ accession numbers for the sequences reported in this paper are EU627685 and EU636682?EU636696. Supplementary material is available with the online version of this paper.
AI Research

Clinical trials of foreign-made flu vaccine to start in Japan next month
8/29/08 Japan Today--Clinical trials of a prepandemic flu vaccine developed by GlaxoSmithKline will start in Japan next month, the British company?s Japan unit said Thursday. GlaxoSmithKline KK plans to file an application with the Ministry of Health, Labor and Welfare possibly next year hoping the vaccine will be adopted for the Japanese government?s stockpiling program.
Vaccines

HHS, Homeland Security Release Pandemic Influenza Vaccine Guidance
8/28/08 Occupational Health and Safety--The U.S. Departments of Health and Human Services and Homeland Security have released Guidance on Allocating and Targeting Pandemic Influenza Vaccine. The purpose of the guidance is to provide a planning framework to help state, tribal, local, and community leaders ensure that vaccine allocation and use will reduce the impact of a pandemic on public health.
Vaccines

How Long Does Flu Immunity Last?
8/27/08 Time--Every year in the fall, physicians dispense a new flu vaccine. Typically it is designed to protect against the three flu strains that epidemiologists predict will be the most pervasive that season. But how often have patients received the flu shot, only to catch a bad illness anyway? The problem is that cold and flu viruses mutate so rapidly that sometimes they're unrecognizable to the antibodies created by the body in response to any particular vaccine. It turns out, however, that those antibodies ? unlike those against illnesses like tetanus or whooping cough ? can provide a formidable and life-long defense against the flu, as long as they're pitted against the correct strain. For an explanation, TIME asks Eric Altschuler, assistant professor of physical medicine and rehabilitation at the University of Medicine and Dentistry of New Jersey, and co-author of a recent paper in Nature about antibodies to the 1918 pandemic flu virus.Q: How long do flu antibodies last?
AI Research


Full Text of Articles follow ...


Quid Novi

Iraq: Reports of Chicken Die-offs on 70 Farms


8/29/08 ARGUS--A local source reported chicken die-offs due to ?viral respiratory asphyxia? on 70 farms in Al Mahawil district in Babil province. The Secretary of the local council indicated that the death rate is 80% per farm, which led to closure and abandoning of farms by the owners due to the losses incurred. According to the source, the Secretary attributed the spread of the disease to lack of veterinary follow-up, in-effective vaccines that are available through the agricultural department, and poor quality feed, which is of unknown origin and mostly expired.

An international source reported that the Director of Babel veterinary hospital denied the news about the spread of a viral disease on 70 poultry farms in Babel. The Director of the veterinary hospital also denied the existence of any disease under the name of ?Respiratory Asphyxia?. He added that legal actions will be taken against 2 local media sources for publishing false news about the disease.

Article URL(s)

http://www.iraqdirectory.com/DisplayNewsAr.aspx?id=6689

http://www.sotaliraq.com/iraqnews.php?id=25009

http://www.alitthad.com/paper.php?name=News&file=article&sid=42724

Regional Reporting and Surveillance

Panama: Ministry Reserves 200,000 Doses of Tamiflu


8/29/08 ARGUS--A national source reports that the Ministry of Health has reserves of more than 200,000 individual doses of oseltamivir (Tamiflu) in the event of an avian influenza pandemic. In addition, the Gorgas Institute Commemorative will rely on a regional investigative lab to conduct a diagnosis in less than 24 hours. There has not been a case of avian influenza registered in Panama, but Panama is part of the migratory route for millions of birds from North to South America between September and October. The Ministry of Agricultural Development has identified locations where birds nest and feed en route along the Caribbean coast, far from farmlands. More than 7,000 samples of migratory birds have been analyzed; all tested negative for AI.

Article URL(s)

http://www.elsiglo.com/siglov2/Nacion.php?idsec=1&fechaz=26-08-2008&idnews=79521

Quid Novi

Indonesia: Reports of poultry die-off in North Sumatera


8/29/08 ARGUS--A local source reported that multi-focal bird die-offs in Sarang Giting village settlements (Dolok Masihul district, Serdang Bedagai regency, North Sumatera province) have killed an unspecified number of chickens since 25 August. These die-offs continue to occur, with an increasing number of chickens dying every day. Local authorities have yet to determine what is causing the die-offs but have conducted fumigation to curb ?any outbreaks?.

Article URL(s)
http://hariansib.com/2008/08/28/ayam-peliharaan-penduduk-di-dolok-masihul-mati-mendadak/

Regional Reporting and Surveillance

OIE: UK Follow Up #3 (Final Report)


Highly pathogenic avian influenza,
United Kingdom

Information received on 28/08/2008 from Dr Nigel Gibbens, Chief Veterinary Officer, Department for Environment, Food and Rural Affairs, Department for Environment, Food and Rural Affairs, LONDON, United Kingdom

Summary
Report type Follow-up report No. 3 (Final report)
Start date 22/05/2008
Date of first confirmation of the event 04/06/2008
Report date 28/08/2008
Date submitted to OIE 28/08/2008
Date event resolved 20/08/2008
Reason for notification New strain of a listed disease
Causal agent Highly pathogenic avian influenza virus
Serotype H7N7
Nature of diagnosis Laboratory (advanced)
This event pertains to the whole country
Related reports

* Immediate notification (05/06/2008)
* Follow-up report No. 1 (13/06/2008)
* Follow-up report No. 2 (18/07/2008)
* Follow-up report No. 3 (28/08/2008)

Outbreaks There are no new outbreaks in this report

Epidemiology
Source of the outbreak(s) or origin of infection

* Unknown or inconclusive

Epidemiological comments The final cleansing and disinfection on the single infected premises was completed on 20 August 2008.
The epidemiology report is available at: http://www.defra.gov.uk/animalh/index.htm.
The surveillance zone and disease control area restrictions that were put in place following the outbreak were lifted on 8 July 2008. Surveillance has shown that infection appears to have been contained to the single premises.

Control measures
Measures applied

* Stamping out
* Movement control inside the country
* Screening
* Zoning
* Disinfection of infected premises/establishment(s)
* Vaccination prohibited
* No treatment of affected animals

Measures to be applied

* No other measures

Future Reporting
The event is resolved. No more reports will be submitted.

Regional Reporting and Surveillance

VIETNAM: Uphill battle to raise awareness of bird flu


8/29/08 Irin News--The key message that needs to be heard is that Avian Influenza (AI) is endemic in Vietnam and needs to be controlled, say UN officials involved in the battle to identify and contain avian influenza outbreaks.

According to the Vietnam Partnership for Avian and Human Influenza (PAHI), three provinces have reported new outbreaks in recent weeks. Since the start of 2008, 44 districts in 26 of Vietnam's 64 provinces have reported outbreaks, highlighting the challenge the country faces in controlling the disease.

Overall since 2003, Vietnam has had 106 cases of human avian flu and 52 deaths.

Yet compared to 2004 and 2005, when 90 cases of human infection occurred with 39 deaths, [] Vietnam has made huge strides, according to David Payne, the UN Development Programme avian influenza specialist in Hanoi, "with only five infections since March 2008, all of whom died".

Payne gives the Vietnamese government high marks for recognising early on the severity of the AI problem and turning to the UN and the humanitarian community for advice and support.

"The office of the UN resident representative for Vietnam - with the World Health Organization (WHO), the Food and Agriculture Organization (FAO) and the UN Children?s Fund (UNICEF) taking the lead - has worked closely with the Ministry of Agriculture and Rural Development and other relevant ministries," said Payne, adding that UN agencies have taken a united approach to assisting the government.

The key strategy of the government and UN agencies in confronting avian influenza is the Viet Nam Integrated National Operational Programme for Avian and Human Influenza 2006-2010, known as the "Greenbook".

It is a US$250 million five-year programme funded initially principally by the Japan International Cooperation Agency (JICA) but now including the World Bank and other donors. It includes improving surveillance abilities, culling and market controls and the goal of vaccinating 30 million poultry twice a year. It is also designed to strengthen overall health capacity, train epidemiologists and establish laboratories.

Awareness raising efforts

An aggressive public awareness programme overseen by the UN Children's Fund (UNICEF) is integral to the strategy.

UNICEF has supported the rental of mobile vans equipped with loudspeakers that travelled around key districts in eight high-risk provinces in the north in March/April 2008, informing residents of ways to safeguard against avian influenza transmission. They have also distributed posters and brochures.

According to Tran Minh Thu, UNICEF's avian influenza communications officer in Hanoi, UNICEF is working with the National Centre of Heath and Education on a variety of awareness raising efforts.

"In May 2007, we provided support for a mass radio and TV awareness campaign and also helped to train provincial and district level health staff on safeguards against AI and human avian influenza and in honing their communication skills," said Thu.

The key messages include hand washing, safe and sanitary slaughter of poultry, thorough cooking of meat, and keeping children away from contact with poultry and their faeces.


Photo: FAO
Community forums have proven instrumental in raising wareness levels of bird flu
Ha Nam Province

In Ha Nam Province, just south of Hanoi, the director of its Centre of Health Education, Pham Quang Mae, told IRIN that since 2003 the province had had five outbreaks of avian influenza with mass culling, and five human deaths.

Mae praised UNICEF's efforts but told IRIN: "We think people have become complacent. They still throw dead chickens into the rivers and the canals? "People are aware of the need to wash their hands but many don't? I believe that things will change, but it will take time."

UNICEF is currently evaluating with the government the next steps in raising community awareness, but Do Thi Dung, vice-director for communications for Ha Nam Province's Centre of Health Education said: "I think the campaign should now involve community health workers at the commune level, not just the provincial and district levels."

In one project, funded by the US Agency for International Development (USAID), UNICEF is helping to do just that.

Tran Thi Cham, chairwoman of the Women's Union in Ha Nam Province, told IRIN, "Since 2007, with the help of UNICEF, we've been training the women's union staff down to the commune level on avian influenza, organising and raising awareness. We do it through poems, singing and plays."

The Women's Union in Ha Nam Province has 24 "clubs" - groupings of 60 women - and hopes to expand the number to address the avian influenza problem.

Bui Thi Hang, Ha NaKim Bang District Women's Communication head, said: "Women are the ones who are directly involved in raising poultry so the Women's Union is the most effective means in reaching women with the key messages."

UNICEF acknowledges behaviour change is a long-term challenge. This was demonstrated on a visit to Hoang Thi Tien's duck farm in Que Commune, Kim Bang District.

"I sell the birds and slaughter them at home." Tien told IRIN. She says she vaccinates her chicks, which she buys from a safe hatchery, and even cleanses her motorbike after transporting the chickens and washes her boots with detergent. Nonetheless, her protective gloves are well-worn with tears all over. Worst of all, she lives no more than 100 metres from Le Thi Qanh's farm, and their ducks share a common waterway. Only recently Qanh's flock of 130 ducks were culled because of an AI outbreak.

"I just don't think I will have an avian flu outbreak here, Tien told IRIN. "It happens to others."

Regional Reporting and Surveillance

Kurdistan: Poultry production capacity falls


8/28/08 Kurdish Globe--Lack of basic services on poultry farms has, in addition to shutting down many farms, increased cost of production and decreased quantity of production.

The amount of imported frozen chicken is on the increase as the searing summer and lack of fuel and electricity have forced the majority of Kurdistan Region's poultry farms to close their doors.

According to statistic published by the Kurdistan Association for Raising Poultry, during the three months of May, June, and July 2007, around 1,080,000 chickens were produced in Suleimaniya's poultry farms, while during the same period of 2008, only 545,000 chickens re produced in those poultries.

This 50% decrease during one single year alarms owners and agriculture economists.

As one of the very few sectors of local production, poultry production used to satisfy most of the region's demand; the rest was imported from outside, and particularly from Brazil.

However, as the bird flu became a threat to the region's residents in 2006, imported chicken meat was banned by the Health Ministry as a preventive measure against the transmission of the epidemic from already affected regions. Hence, people were forced to buy locally produced chicken meat and eggs only. But even after the bird flu threat was over and imported chicken and eggs regained entry into Kurdistan, people were still afraid to consume imported poultry products and stuck to local products, something that continues today.

But now, as local production capacity has fallen significantly, the question is whether consumers can easily shift back to Brazilian chicken or are ready to pay more for local chicken?

Lack of basic services on poultry farms has, in addition to shutting down many farms, increased cost of production and decreased quantity of production. The increasing sales price in the market has already opened the way for imported frozen chicken.

Awat Hama Aziz, deputy director general of animal resources and health in Suleimaniya, says that in spite of the extraordinarily high temperatures of this summer, the public sector has failed to supply sufficient electricity to most of the farms and those who have electricity are using their own power generators. Besides, the farm owners are not able to afford all this fuel consumption of their generators.

"Most of the owners' capital goes to providing electricity and fuel," Aziz told a local newspaper. "The process of raising young chickens costs too much and using private power generators is a main part of the production cost, which in turn pushes the selling price up."

Aziz added that this lack of electricity and fuel is despite the fact that poultry farms are in need of 24-hour supply.

"This is because of many reasons; for example, the air refreshment system needs electricity to operate. Farms also need to use fridges and freezers in addition to food preparation machines," said Aziz.

Sarwar Karim Agha, head of Kurdistan Association for Poultry Raising, confirms Aziz's claims and says that if the government provides the poultry farms with continuous power supply, the farms would save US$1,800 per one production cycle.

Yet another challenge facing poultry farm owners is the notable increase in the price of corn, which is the main food for chickens. According to what Agha says, a chicken consumes between 4 and 5 kilograms of corn in 50 days, which is a very high level of corn consumption.

The Kurdistan Regional Government (KRG) has allegedly allocated US$16 million for 800 projects for the production and preservation of animal protein in all three provinces of Erbil, Suleimaniya, and Duhok. However, as Agha claims, this amount has not been spent and none of the projects have entered the implementation phase. He also expressed his concern about the government's carelessness about poultry farms and claimed that it has to promote local production.

Many investors in local production sectors as well as economists are concerned about the fact that the KRG doesn't yet have a law to protect local production against imports and imported goods have already taken control over the Kurdish market. Even many economists believe that the system in the region is exactly opposite to most other economic systems in the world as it promotes imports and foreign products and favors them over locally produced goods.

All these difficulties facing poultry farms have disappointed investors and thus become threats to the poultry production in Kurdistan Region.

AI Research

Genotypic diversity of H5N1 highly pathogenic avian influenza viruses


8/29/08 Journal of General Virology--[Abstract]--Besides enormous economic losses to the poultry industry, recent H5N1 highly pathogenic avian influenza viruses (HPAIVs) originating in eastern Asia have posed serious threats to public health. Up to April 17, 2008, 381 human cases had been confirmed with a mortality of more than 60 %. Here, we attempt to identify potential progenitor genes for H5N1 HPAIVs since their first recognition in 1996; most were detected in the Eurasian landmass before 1996. Combinations among these progenitor genes generated at least 21 reassortants (named H5N1 progenitor reassortant, H5N1-PR1?21). H5N1-PR1 includes A/Goose/Guangdong/1/1996(H5N1). Only reassortants H5N1-PR2 and H5N1-PR7 were associated with confirmed human cases: H5N1-PR2 in the Hong Kong H5N1 outbreak in 1997 and H5N1-PR7 in laboratory confirmed human cases since 2003. H5N1-PR7 also contains a majority of the H5N1 viruses causing avian influenza outbreaks in birds, including the first wave of genotype Z, Qinghai-like and Fujian-like virus lineages. Among the 21 reassortants identified, 13 are first reported here. This study illustrates evolutionary patterns of H5N1 HPAIVs, which may be useful toward pandemic preparedness as well as avian influenza prevention and control.

{dagger}Present address: Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.

The GenBank/EMBL/DDBJ accession numbers for the sequences reported in this paper are EU627685 and EU636682?EU636696.

Supplementary material is available with the online version of this paper.

Regional Reporting and Surveillance

UK: Bird flu 'will stay in Britain for five years'


8/29/08 Edinburgh News--BIRD flu will arrive in Britain within months and stay for at least five years, the government's chief scientific adviser has predicted.

Professor Sir David King warned the disease could become "endemic" in the UK as it is in China, but he said he did not expect it to be as damaging as foot-and-mouth was in 2001.

Both he and Environment, Farming and Rural Affairs Secretary Margaret Beckett have said the vaccination of poultry is being kept under review but warn it may not be very effective.

Speaking at the Annual Conference of the Annual Farmers' Union, Sir David said: "I would anticipate that avian flu will arrive at some point in the UK. We also have to anticipate that it will be here for five years plus.

"We are talking about the possibility of this disease being endemic here in the UK as it was in China. It's a long-term factor."

He said he expected bird flu to reach the UK in months rather than in days or weeks due to the pattern of bird migration.

Sir David said: "I feel - and I am prepared to stand here and say this - rather more optimistic about a potential H5NI outbreak in poultry holders in the UK than I would have been about foot-and-mouth back in 2001."

Vaccines

Clinical trials of foreign-made flu vaccine to start in Japan next month


8/29/08 Japan Today--Clinical trials of a prepandemic flu vaccine developed by GlaxoSmithKline will start in Japan next month, the British company?s Japan unit said Thursday. GlaxoSmithKline KK plans to file an application with the Ministry of Health, Labor and Welfare possibly next year hoping the vaccine will be adopted for the Japanese government?s stockpiling program.

Currently, all prepandemic vaccines stockpiled by the government are domestically developed ones. GSK?s vaccine would be the first foreign-made one to be stockpiled in Japan. The government has stored prepandemic flu vaccines for about 20 million people and plans to add vaccines for another 10 million people. Like domestically produced vaccines, GSK?s vaccine was made from the H5N1 strain of bird flu virus, which has been spreading in Asia. But its vaccine has a uniquely-developed immune-enhancing agent, GSK says.

Regional Reporting and Surveillance

FAO assures Bangladesh of support towards food security


8/29/08 Xinhua--A visiting high official of United Nation's Food and Agriculture Organization (FAO) Friday assured Bangladesh of providing necessary support in its efforts to ensure food security.

Making a courtesy call on caretaker government Finance and Planning Adviser Mirza Azizul Islam, FAO Asia Pacific Region head Hey Cheng Chyue also assured to provide assistance in the country's fight against bird flu, ongoing agriculture census and agriculture research activities, according to private news agency UNB.

"Bangladesh has got what is necessary for food security. If the country can utilize the potential, food security will be ensured, "he told reporters after the meeting.

Azizul said that the FAO official emphasized on developing hybrid as well as deep and saline water-resistant seeds to increase food production in the country while assuring technical assistance in this regard, if necessary.

He said Cheng appreciated Bangladesh for taking food security measures like increasing endowment fund for agriculture research and climate change fund.

Vaccines

HHS, Homeland Security Release Pandemic Influenza Vaccine Guidance


8/28/08 Occupational Health and Safety--The U.S. Departments of Health and Human Services and Homeland Security have released Guidance on Allocating and Targeting Pandemic Influenza Vaccine. The purpose of the guidance is to provide a planning framework to help state, tribal, local, and community leaders ensure that vaccine allocation and use will reduce the impact of a pandemic on public health.

Target groups are defined in the guidance by a common occupation, type of service, age group, or risk level and are clustered into four broad categories: homeland and national security, health care and community support services, critical infrastructures, and the general population. These four categories together cover the entire population.

Across these categories, according to the document, vaccine should be allocated and administered according to tiers where all groups designated for vaccination within a tier have equal priority for vaccination. Groups within tiers vary depending on pandemic severity.

For more information, visit www.pandemicflu.gov/vaccine/allocationguidance.pdf.

Regional Reporting and Surveillance

Australia: The battle to secure our borders against a tiny, but lethal, enemy force


8/28/08 Sydney Morning Herald--We once thought the battle against infectious disease was won. Security experts now tell us this is not so. In a globalised, interconnected world - where people, trade and goods move around like never before - people, their pets, livestock, wildlife and crops are still vulnerable.

Animal and human diseases and insects respect no national borders. They move easily across time and space. Infections and insect pests once thought limited to certain parts of the world are now able to spread easily and quickly to Australia. And we still do not fully appreciate that human health is intimately connected to animal health and that wildlife and domestic animals and insects continue play a huge part in whether our livestock and crops prosper and whether we remain healthy.

SARS, Avian influenza and equine flu demonstrated quite clearly how poorly prepared we are for such events and the vulnerability of our trade, tourism, agricultural industry, biodiversity and human health to introduced diseases.

There are many potential threats to Australia's biosecurity. Some, such as invasive alien species, invertebrate and vertebrate pests, as well as animal infections, threaten the viability of our wildlife and rural industries, on occasions reaching out to affect us as well. The equine flu disaster and the Hendra virus outbreak in Queensland demonstrate this only too clearly. Others, such as avian influenza or a new pandemic of human flu, threaten the health of millions of citizens.

Most Australians believe that only developing nations have to worry about insect-borne diseases. Yet over the last 200 years, mosquitoes and fleas have been responsible for thousands of deaths and sickened millions of people in Australia.

We remain vulnerable to a wide range of mosquito-borne diseases such as dengue, Ross River virus and Barmah Forest virus. Naturally occurring infectious diseases and invasive pests are the predominant threat, but what about insects or disease purposely released for political reasons? You might think it far-fetched, but perhaps our next terrorist attack will come on six legs and target our agricultural industry.

One of the cheapest, most easily obtained and potentially most destructive means available to terrorists is not anthrax or smallpox, but insects. They are easy to sneak into the country, they reproduce and spread quickly, and the effect would be devastating for livestock and crops.

The economic consequences of such an attack could be vast. The social, economic and political impact of human disease outbreaks, whether natural or deliberate, could well be greater. Infectious diseases do not just make our bodies sick, they can also poison the well of community spirit and damage our faith in governments.

Natural disasters such as bushfires, floods and droughts bring out the best in people, but when everyone is a potential carrier of deadly germs, there is less enthusiasm for volunteer relief services.

Most people would assume that infectious diseases could only seriously affect the politics of the developing world, yet Australian history is littered with examples of widespread public hysteria and disputes between local, State and Commonwealth governments over how best to respond to epidemics.

The lessons from this are clear. Infectious disease is never far away. To protect all Australians we need to better understand the ecology of emerging infections, the significance of wild and domestic animals in the disease transmission process and the vulnerability of Australia to infectious disease, whether natural or deliberate, as well as to insects and alien species.

The sooner we appreciate the critical links between all these things the sooner we will be able to develop a coordinated and all encompassing national and regional biosecurity surveillance and response system that provides 24/7 protection for all Australians.

Peter Curson is professor of population and security, and Jonathan Herington is projects officer (biosecurity), in the Centre for International Security Studies at the University of Sydney.

AI Research

How Long Does Flu Immunity Last?


8/27/08 Time--Every year in the fall, physicians dispense a new flu vaccine. Typically it is designed to protect against the three flu strains that epidemiologists predict will be the most pervasive that season. But how often have patients received the flu shot, only to catch a bad illness anyway? The problem is that cold and flu viruses mutate so rapidly that sometimes they're unrecognizable to the antibodies created by the body in response to any particular vaccine. It turns out, however, that those antibodies ? unlike those against illnesses like tetanus or whooping cough ? can provide a formidable and life-long defense against the flu, as long as they're pitted against the correct strain. For an explanation, TIME asks Eric Altschuler, assistant professor of physical medicine and rehabilitation at the University of Medicine and Dentistry of New Jersey, and co-author of a recent paper in Nature about antibodies to the 1918 pandemic flu virus.Q: How long do flu antibodies last?

A: According to our study, it appears they can last the entire lifespan of the human organism ? 90 years plus.

In our study we were looking for antibodies to the 1918 flu. This flu virus was reconstructed a number of years ago in the lab, so we were able to test to see if 90 years later we could still find antibodies. I recruited survivors, people who were born in 1915 or earlier and thus presumably survived the 1918 flu. We found that virtually all the people born in 1915 or earlier ? about 90% of them ? had good "titers" to the 1918 flu, which means they still had reasonably high concentrations of the antibodies in their blood, whereas among controls, people who were born in 1926 or later, it was only about 10%. That was really quite a remarkable finding.

The important question in this study is whether the antibodies still work after all that time, and I think my colleagues really found some very decisive results. I sent the blood samples from the survivors to my colleagues, Chris Basler at Mount Sinai, who's a professor of microbiology, and James Crowe at Vanderbilt, who's in pediatrics, microbiology and immunology. Dr Crowe and his colleagues at Vanderbilt isolated five different antibodies to the 1918 flu. Then Dr. Basler and colleagues looked at how those antibodies bind to the virus. It was quite strong and specific. We tried to compare it to other viruses, studying, for example, whether the antibody would bind to the flu of 1999 or to earlier ones, like the 1943 flu. Most antibodies bound to 1918, and only 1918. One of them bound, but much more weakly, to a couple of others. So that was really quite good evidence, we thought.

I think the most definitive experiment we did was in mice. If you give mice the 1918 influenza, it kills them quite rapidly. It's very lethal. Terry Tumpey at the Centers for Disease Control and Prevention infected mice with the various strains that made up the 1918 flu. Then we treated the mice either with our five antibodies or with controls. (There were two controls. One was human gamma globulin, which are just pooled antibodies that bind to a lot of different things. The other was the antibody to one of the modern bird flus.) And all of the control-treated mice, whether they got the gamma globulin or the bird-flu antibody, they all died. All of those mice died. Meanwhile all the mice that were treated with the highest doses of our antibodies survived. That's really very strong evidence ? the strongest ? that these antibodies are functional against this virus.

I think that diseases, other viruses and other pathogens, can behave differently. Antibodies are made by something called memory B cells, and the memory B cells for the 1918 flu clearly live for the lifespan of the human organism, which is wonderful. It raises important questions for looking at other pathogens, however, and it's important to try to look at these questions for different pathogens individually. Evidence shows it's important to get a regular tetanus booster, for example. Still, our new study may suggest another angle to look at things, which is how long do memory B cells last for this or that? Maybe there's some underlying biology that could explain why one thing might last longer than another.

Podcast
How Long Do Antibodies Last?

TIME talks to Eric Altschuler, assistant professor of physical medicine and rehabilitation at the University of Medicine and Dentistry of New Jersey

UNCLASSIFIED

Aug 28, 2008

DNI Avian Influenza Daily Digest

UNCLASSIFIED

Intelink Avian Influenza Daily Digest

Avian Influenza Daily Digest

August 28, 2008 19:40 GMT

This digest is produced by the United States Government, Office of the Director of National Intelligence, Washington DC, USA. Articles and resource documents in this digest are from open sources and unclassified.

This digest contains raw open source content and is not an evaluated intelligence product. Readers are encouraged to contribute updates and/or clarifications that will be posted in subsequent issues of the digest. Articles may contain copyrighted material, further dissemination outside government channels may be prohibited without permission from the copyright owners.

Please note some links may only work while connected to the Intelink network.

Unsubscribe/Subscribe to the AI Digest
Contact AI Digest Editor/Contribute (U) Information
Contribute (U) Updates/Clarifications to a previously reported article
Contribute (U) Information anonymously


Intelink Avian Influenza Resources:
U.S. Govt. IC: Intelink AI/Pandemic page https://www.intelink.gov/mypage/avianflu


Article Summaries ...

Regional Reporting and Surveillance

Australia: The battle to secure our borders against a tiny, but lethal, enemy force
8/28/08 Sydney Morning Herald--We once thought the battle against infectious disease was won. Security experts now tell us this is not so. In a globalised, interconnected world - where people, trade and goods move around like never before - people, their pets, livestock, wildlife and crops are still vulnerable.
Regional Reporting and Surveillance

Science and Technology

HHS, Homeland Security Release Pandemic Influenza Vaccine Guidance
8/28/08 Occupational Health and Safety--The U.S. Departments of Health and Human Services and Homeland Security have released Guidance on Allocating and Targeting Pandemic Influenza Vaccine. The purpose of the guidance is to provide a planning framework to help state, tribal, local, and community leaders ensure that vaccine allocation and use will reduce the impact of a pandemic on public health.
Vaccines

How Long Does Flu Immunity Last?
8/27/08 Time--Every year in the fall, physicians dispense a new flu vaccine. Typically it is designed to protect against the three flu strains that epidemiologists predict will be the most pervasive that season. But how often have patients received the flu shot, only to catch a bad illness anyway? The problem is that cold and flu viruses mutate so rapidly that sometimes they're unrecognizable to the antibodies created by the body in response to any particular vaccine. It turns out, however, that those antibodies ? unlike those against illnesses like tetanus or whooping cough ? can provide a formidable and life-long defense against the flu, as long as they're pitted against the correct strain. For an explanation, TIME asks Eric Altschuler, assistant professor of physical medicine and rehabilitation at the University of Medicine and Dentistry of New Jersey, and co-author of a recent paper in Nature about antibodies to the 1918 pandemic flu virus.Q: How long do flu antibodies last?
AI Research


Full Text of Articles follow ...


Vaccines

HHS, Homeland Security Release Pandemic Influenza Vaccine Guidance


8/28/08 Occupational Health and Safety--The U.S. Departments of Health and Human Services and Homeland Security have released Guidance on Allocating and Targeting Pandemic Influenza Vaccine. The purpose of the guidance is to provide a planning framework to help state, tribal, local, and community leaders ensure that vaccine allocation and use will reduce the impact of a pandemic on public health.

Target groups are defined in the guidance by a common occupation, type of service, age group, or risk level and are clustered into four broad categories: homeland and national security, health care and community support services, critical infrastructures, and the general population. These four categories together cover the entire population.

Across these categories, according to the document, vaccine should be allocated and administered according to tiers where all groups designated for vaccination within a tier have equal priority for vaccination. Groups within tiers vary depending on pandemic severity.

For more information, visit www.pandemicflu.gov/vaccine/allocationguidance.pdf.

Regional Reporting and Surveillance

Australia: The battle to secure our borders against a tiny, but lethal, enemy force


8/28/08 Sydney Morning Herald--We once thought the battle against infectious disease was won. Security experts now tell us this is not so. In a globalised, interconnected world - where people, trade and goods move around like never before - people, their pets, livestock, wildlife and crops are still vulnerable.

Animal and human diseases and insects respect no national borders. They move easily across time and space. Infections and insect pests once thought limited to certain parts of the world are now able to spread easily and quickly to Australia. And we still do not fully appreciate that human health is intimately connected to animal health and that wildlife and domestic animals and insects continue play a huge part in whether our livestock and crops prosper and whether we remain healthy.

SARS, Avian influenza and equine flu demonstrated quite clearly how poorly prepared we are for such events and the vulnerability of our trade, tourism, agricultural industry, biodiversity and human health to introduced diseases.

There are many potential threats to Australia's biosecurity. Some, such as invasive alien species, invertebrate and vertebrate pests, as well as animal infections, threaten the viability of our wildlife and rural industries, on occasions reaching out to affect us as well. The equine flu disaster and the Hendra virus outbreak in Queensland demonstrate this only too clearly. Others, such as avian influenza or a new pandemic of human flu, threaten the health of millions of citizens.

Most Australians believe that only developing nations have to worry about insect-borne diseases. Yet over the last 200 years, mosquitoes and fleas have been responsible for thousands of deaths and sickened millions of people in Australia.

We remain vulnerable to a wide range of mosquito-borne diseases such as dengue, Ross River virus and Barmah Forest virus. Naturally occurring infectious diseases and invasive pests are the predominant threat, but what about insects or disease purposely released for political reasons? You might think it far-fetched, but perhaps our next terrorist attack will come on six legs and target our agricultural industry.

One of the cheapest, most easily obtained and potentially most destructive means available to terrorists is not anthrax or smallpox, but insects. They are easy to sneak into the country, they reproduce and spread quickly, and the effect would be devastating for livestock and crops.

The economic consequences of such an attack could be vast. The social, economic and political impact of human disease outbreaks, whether natural or deliberate, could well be greater. Infectious diseases do not just make our bodies sick, they can also poison the well of community spirit and damage our faith in governments.

Natural disasters such as bushfires, floods and droughts bring out the best in people, but when everyone is a potential carrier of deadly germs, there is less enthusiasm for volunteer relief services.

Most people would assume that infectious diseases could only seriously affect the politics of the developing world, yet Australian history is littered with examples of widespread public hysteria and disputes between local, State and Commonwealth governments over how best to respond to epidemics.

The lessons from this are clear. Infectious disease is never far away. To protect all Australians we need to better understand the ecology of emerging infections, the significance of wild and domestic animals in the disease transmission process and the vulnerability of Australia to infectious disease, whether natural or deliberate, as well as to insects and alien species.

The sooner we appreciate the critical links between all these things the sooner we will be able to develop a coordinated and all encompassing national and regional biosecurity surveillance and response system that provides 24/7 protection for all Australians.

Peter Curson is professor of population and security, and Jonathan Herington is projects officer (biosecurity), in the Centre for International Security Studies at the University of Sydney.

AI Research

How Long Does Flu Immunity Last?


8/27/08 Time--Every year in the fall, physicians dispense a new flu vaccine. Typically it is designed to protect against the three flu strains that epidemiologists predict will be the most pervasive that season. But how often have patients received the flu shot, only to catch a bad illness anyway? The problem is that cold and flu viruses mutate so rapidly that sometimes they're unrecognizable to the antibodies created by the body in response to any particular vaccine. It turns out, however, that those antibodies ? unlike those against illnesses like tetanus or whooping cough ? can provide a formidable and life-long defense against the flu, as long as they're pitted against the correct strain. For an explanation, TIME asks Eric Altschuler, assistant professor of physical medicine and rehabilitation at the University of Medicine and Dentistry of New Jersey, and co-author of a recent paper in Nature about antibodies to the 1918 pandemic flu virus.Q: How long do flu antibodies last?

A: According to our study, it appears they can last the entire lifespan of the human organism ? 90 years plus.

In our study we were looking for antibodies to the 1918 flu. This flu virus was reconstructed a number of years ago in the lab, so we were able to test to see if 90 years later we could still find antibodies. I recruited survivors, people who were born in 1915 or earlier and thus presumably survived the 1918 flu. We found that virtually all the people born in 1915 or earlier ? about 90% of them ? had good "titers" to the 1918 flu, which means they still had reasonably high concentrations of the antibodies in their blood, whereas among controls, people who were born in 1926 or later, it was only about 10%. That was really quite a remarkable finding.

The important question in this study is whether the antibodies still work after all that time, and I think my colleagues really found some very decisive results. I sent the blood samples from the survivors to my colleagues, Chris Basler at Mount Sinai, who's a professor of microbiology, and James Crowe at Vanderbilt, who's in pediatrics, microbiology and immunology. Dr Crowe and his colleagues at Vanderbilt isolated five different antibodies to the 1918 flu. Then Dr. Basler and colleagues looked at how those antibodies bind to the virus. It was quite strong and specific. We tried to compare it to other viruses, studying, for example, whether the antibody would bind to the flu of 1999 or to earlier ones, like the 1943 flu. Most antibodies bound to 1918, and only 1918. One of them bound, but much more weakly, to a couple of others. So that was really quite good evidence, we thought.

I think the most definitive experiment we did was in mice. If you give mice the 1918 influenza, it kills them quite rapidly. It's very lethal. Terry Tumpey at the Centers for Disease Control and Prevention infected mice with the various strains that made up the 1918 flu. Then we treated the mice either with our five antibodies or with controls. (There were two controls. One was human gamma globulin, which are just pooled antibodies that bind to a lot of different things. The other was the antibody to one of the modern bird flus.) And all of the control-treated mice, whether they got the gamma globulin or the bird-flu antibody, they all died. All of those mice died. Meanwhile all the mice that were treated with the highest doses of our antibodies survived. That's really very strong evidence ? the strongest ? that these antibodies are functional against this virus.

I think that diseases, other viruses and other pathogens, can behave differently. Antibodies are made by something called memory B cells, and the memory B cells for the 1918 flu clearly live for the lifespan of the human organism, which is wonderful. It raises important questions for looking at other pathogens, however, and it's important to try to look at these questions for different pathogens individually. Evidence shows it's important to get a regular tetanus booster, for example. Still, our new study may suggest another angle to look at things, which is how long do memory B cells last for this or that? Maybe there's some underlying biology that could explain why one thing might last longer than another.

Podcast
How Long Do Antibodies Last?

TIME talks to Eric Altschuler, assistant professor of physical medicine and rehabilitation at the University of Medicine and Dentistry of New Jersey

UNCLASSIFIED

Aug 27, 2008

DNI Avian Influenza Daily Digest

UNCLASSIFIED

Intelink Avian Influenza Daily Digest

Avian Influenza Daily Digest

August 27, 2008 17:45 GMT

This digest is produced by the United States Government, Office of the Director of National Intelligence, Washington DC, USA. Articles and resource documents in this digest are from open sources and unclassified.

This digest contains raw open source content and is not an evaluated intelligence product. Readers are encouraged to contribute updates and/or clarifications that will be posted in subsequent issues of the digest. Articles may contain copyrighted material, further dissemination outside government channels may be prohibited without permission from the copyright owners.

Please note some links may only work while connected to the Intelink network.

Unsubscribe/Subscribe to the AI Digest
Contact AI Digest Editor/Contribute (U) Information
Contribute (U) Updates/Clarifications to a previously reported article
Contribute (U) Information anonymously


Intelink Avian Influenza Resources:
U.S. Govt. IC: Intelink AI/Pandemic page https://www.intelink.gov/mypage/avianflu


Article Summaries ...

Quid Novi

Afghanistan: H5N1 reported in Khwost Province

Indonesia: die-off reported in Wonogiri

Indonesia: Die-offs reported in Lebong and Bengkulu city

OIE: Benin Immediate Notification

Regional Reporting and Surveillance

Yemen: World Bank gifts $1 mln to strengthen precaution against bird flu
8/27/08 Saba--World Bank announced here on Tuesday that it would gift Yemen about $ 1,000,080 to support the country's efforts to take precautionary measures and encountering the bird flu.
Regional Reporting and Surveillance

Vietnam: AI Update
8/27/08 VNS, contributed by email--A strain of the H5N1 virus that posed a high risk of infecting humans and caused an avian flu epidemic in China has appeared in smuggled poultry in Vietnam, state media reported, citing an official from the Animal Health Department Thursday.
Regional Reporting and Surveillance

OIE: Denmark regains AI free status
8/27/08 OIE--Following a single outbreak of low pathogenic H7N1 notifiable avian influenza on April 24, 2008, Denmark, having met the requirements in article 2.7.12.3 of the OIE Terrestrial Animal Health Code, declares having regained its status as a notifiable avian influenza free country on 24 August 2008.
Regional Reporting and Surveillance

Japan: Health ministry to introduce 3,600 respirators for new flu pandemic
8/27/08 Japan Today--The health ministry has decided to introduce about 3,600 respirators at medical institutions across Japan to prepare for the possibility of a new influenza pandemic, ministry officials said Wednesday. The Ministry of Health, Labor and Welfare plans to make budgetary request of about 2 billion yen in fiscal 2009 for the respirators, the officials said. Each of the nearly 360 medical districts in Japan would be given 10 respirators.
Regional Reporting and Surveillance

Nigeria: Poultry Farmers Get N42.5m
8/27/08 All Africa--Eighteen poultry farmers in Ogun, whose birds and eggs were ravaged by Avian influenza, also known as "Bird flu", have received compensation of N42.5 million.
Regional Reporting and Surveillance


Full Text of Articles follow ...


Regional Reporting and Surveillance

Yemen: World Bank gifts $1 mln to strengthen precaution against bird flu


8/27/08 Saba--World Bank announced here on Tuesday that it would gift Yemen about $ 1,000,080 to support the country's efforts to take precautionary measures and encountering the bird flu.

During a meeting gathered here in Sana'a Minister of Agriculture and Irrigation Mansur al-Hawshabi and the WB official of the Rainfed Agriculture and Animal Wealth, the WB stipulated that the government has to approve the Avian Flu National Comprehensive Plan to get this grant.

The meeting also reviewed the implementation progress in the project of the rainfed agriculture and animal wealth and the bank's role in improving the agricultural sector in Yemen.

Quid Novi

Afghanistan: H5N1 reported in Khwost Province


8/27/08 ARGUS--International news sources report that H5N1 avian influenza has been found in poultry in Khwost province. The Ministry of Public Health in Afghanistan has confirmed the reports. The Director added that as part of a plan to ensure the safety of food products destined for public consumption, 3 specialized groups would be inspecting the area. The MoPH of Khwost province asks people not to consume any infected animal meat. A public awareness program is also being developed. The MoPH reported health officials in Kandahar province have acknowledged that a few cases of avian influenza have been found last year in the Kalkan community in Kabol province.

Analyst note: An international source reported that in 2006, 26 cases of H5N1 were reported in backyard poultry in 4 provinces of Afghanistan.

Article URL(s)

http://avianinfluenza.blogfa.com/post-1309.aspx


Quid Novi

Indonesia: die-off reported in Wonogiri


8/27/08 ARGUS--A local source reported a bird die-off of 10 chickens in Pengkol settlement (Pokoh Kidul village, Wonogiri district, Wonogiri regency, Central Java province). Rapid testing of these ten chickens confirmed the presence of avian influenza. Limited culling and disinfectant spraying has been implemented. Reportedly, the local livestock agency could not vaccinate chickens in the area because they did not have any more vaccines due to limited funding.

Article URL(s)

http://www.solopos.co.id/sp_search_tamu.asp?keyword=flu+burung#


Quid Novi

Indonesia: Die-offs reported in Lebong and Bengkulu city


8/27/08 ARGUS--A national source reported that ?hundreds? of chickens died suddenly within the past few days in Lebong regency, Rejang Lebong regency, and Bengkulu city. Rapid testing and laboratory results from Lampung confirmed avian influenza in ?several? of these chickens. Standard control measures have been implemented. However, the head of the local livestock agency refused vaccination against avian influenza because they were worried that these vaccines become sources of infection.

Article URL(s)
http://www.antara.co.id/arc/2008/8/26/sumber-penyebaran-virus-h5n1-di-bengkulu-belum-diketahui


Regional Reporting and Surveillance

Vietnam: AI Update


8/27/08 VNS, contributed by email--A strain of the H5N1 virus that posed a high risk of infecting humans and caused an avian flu epidemic in China has appeared in smuggled poultry in Vietnam, state media reported, citing an official from the Animal Health Department Thursday.

Bui Quang Anh, head of the Ministry of Agricultural and Rural Development's Animal Health Department said at a workshop on fighting poultry and cattle diseases in Hanoi August 26 that the infection mechanism of this highly infectious strain of the H5N1 virus, named seven, had not been found so far.

We are studying more about this strain in our poultry and will soon know the results, said Nguyen Van Cam, the director of the Central Animal Diagnosis Centre.

The avian flu strain that has typically appeared in the Mekong Delta has been strain one, while the Red River Delta has seen strain two, three and four with unknown infection mechanisms.

Anh warned of the high infection rate among poultry, particularly in Mekong Delta provinces.
To prevent the strain from being spread, 242 million doses of H5N1 vaccines and 15 million doses of H5N2 vaccines have been distributed to the localities, according to the department.

At this volume, just 76.5% of poultry will be vaccinated. Localities have typically neglected taking samples of poultry after being vaccinated as only three out of 27 provinces that have undergone bird flu epidemic collected samples to test.

Mekong Delta provinces with a high volume of poultry infected with the H5N1 virus include Vinh Long at 9.25%, Tra Vinh with 8.97%, Soc Trang with 5.32% and Long An with 5%.

So far this year, H5N1 virus has occurred in 74 communes of 51 districts in 27 provinces nationwide, with total poultry dying or being destroyed hitting 75,000.

Vietnam has reported four H5N1 human infections and all of patients died after hospitalization so far this year, raising the country's total infections and deaths since November 2003 to 105 and 51, respectively.

Regional Reporting and Surveillance

OIE: Denmark regains AI free status


8/27/08 OIE--Following a single outbreak of low pathogenic H7N1 notifiable avian influenza on April 24, 2008, Denmark, having met the requirements in article 2.7.12.3 of the OIE Terrestrial Animal Health Code, declares having regained its status as a notifiable avian influenza free country on 24 August 2008.

Regional Reporting and Surveillance

Japan: Health ministry to introduce 3,600 respirators for new flu pandemic


8/27/08 Japan Today--The health ministry has decided to introduce about 3,600 respirators at medical institutions across Japan to prepare for the possibility of a new influenza pandemic, ministry officials said Wednesday. The Ministry of Health, Labor and Welfare plans to make budgetary request of about 2 billion yen in fiscal 2009 for the respirators, the officials said. Each of the nearly 360 medical districts in Japan would be given 10 respirators.

The ministry is studying how many existing respirators owned by Japanese hospitals can be used in the event that a new flu pandemic breaks out. Many people who have contracted the H5N1 strain of avian influenza, which has been spreading in Asia and is feared to mutate into a new flu, have had respiratory problems, making respirators essential in treating them.


Regional Reporting and Surveillance

Nigeria: Poultry Farmers Get N42.5m


8/27/08 All Africa--Eighteen poultry farmers in Ogun, whose birds and eggs were ravaged by Avian influenza, also known as "Bird flu", have received compensation of N42.5 million.

The pandemic affected 123 poultry farms across nine states in the country, while the amount paid to the farmers in Ogun State represented 67.7 per cent of the compensation.

The compensation, it was gathered, was facilitated by the state government, in conjunction with the Federal Government and World Bank.

The state Commissioner for Agriculture, Dr. Kunle Salako, who accompanied by officials of the Federal Ministry of Agriculture, presented the cheque to the beneficiaries.

Salako expressed the government's sympathy to the farmers over the distortion in their operations as a result of the incident.

He said the animal health component of the World Bank was the first agency to respond to the state's distress call over the pandemic.

"The Federal Government followed suit, while the state government did a lot in the provision of funds for the monitoring and the depopulation of the affected farms.

"We have also conducted enlightenment campaigns for the farmers and the birds' sellers," Salako said.

Also speaking, Dr Adedamola Soremekun, State Director of Veterinary Services, said it was sad for the farm owners to have gone through such "harrowing experience".

According to him, the poultry farmers were skeptical when they were told of the control measure to depopulate their farms before they could get any compensation.

"It was difficult for most farmers to agree with the measure, because, most of you believed that the money may never be paid.

"The depopulation is, however, necessary to control the avian influenza. We can all testify that the measure has been effective as the pandemic had been stopped," he said.

One of the farmers, Dr Taiwo Makinde, who expressed appreciation to the government and the World Bank for the financial support.

Makinde said the fear of poor compensation prompted some farmers to attempt to hide their birds from being destroyed.

Reader comment:

Which farmers were the money given? Can you please investigate and list there names. I am a farmer in Ogun State, and every farmer with whom i have had a conversation, non i repaet non have ever had of these compensation.

Quid Novi

OIE: Benin Immediate Notification


Highly pathogenic avian influenza, Benin

Information received on 25/08/2008 from Dr Christophe B. MONSIA, Directeur de l'élevage, Direction de l'élevage, Ministère de l'Agriculture, de l'Elevage et de la Pêche, COTONOU, Benin

Summary

Report type

Immediate notification

Start date

29/07/2008

Date of first confirmation of the event

13/08/2008

Report date

25/08/2008

Date submitted to OIE

25/08/2008

Reason for notification

Reoccurrence of a listed disease

Date of previous occurrence

05/2008

Causal agent

Highly pathogenic avian influenza virus

Serotype

H5

Nature of diagnosis

Laboratory (advanced)

This event pertains to

the whole country

New outbreaks

Summary of outbreaks

Total outbreaks: 1

Outbreak Location and Affected population

LOKOSSA (Lokossa market, Lokossa) : Live chickens purchased at the market in Lokossa as part of the routine surveillance and of the training of managers and other laboratory officials on biomolecular techniques at the Veterinary Laboratory of Parakou.


reverse transcription ? polymerase chain reaction (RT-PCR)

13/08/2008

Positive

Future Reporting

The event is continuing. Weekly follow-up reports will be submitted.


UNCLASSIFIED

Aug 26, 2008

DNI Avian Influenza Daily Digest

UNCLASSIFIED

Intelink Avian Influenza Daily Digest

Avian Influenza Daily Digest

August 26, 2008 14:00 GMT

This digest is produced by the United States Government, Office of the Director of National Intelligence, Washington DC, USA. Articles and resource documents in this digest are from open sources and unclassified.

This digest contains raw open source content and is not an evaluated intelligence product. Readers are encouraged to contribute updates and/or clarifications that will be posted in subsequent issues of the digest. Articles may contain copyrighted material, further dissemination outside government channels may be prohibited without permission from the copyright owners.

Please note some links may only work while connected to the Intelink network.

Unsubscribe/Subscribe to the AI Digest
Contact AI Digest Editor/Contribute (U) Information
Contribute (U) Updates/Clarifications to a previously reported article
Contribute (U) Information anonymously


Intelink Avian Influenza Resources:
U.S. Govt. IC: Intelink AI/Pandemic page https://www.intelink.gov/mypage/avianflu


Article Summaries ...

Regional Reporting and Surveillance

Sierra Leone: Health Ministry on Bird Flu
8/25/08 Sierra Leone News--The Ministry of Health and Sanitation and security personnel along the border chiefdoms in the Kenema District held a one-day Health Education Division Sensitization meeting for personnel in cross border districts on Avian Flu (Bird Flu).
Regional Reporting and Surveillance

Bird flu strain in India, Bangladesh similar
8/25/08 Times of India--The bird flu virus, that caused India's worst Avian Influenza (AI) outbreak this year, has been found to be "a lot similar" to the one that created havoc in Bangladesh.
Regional Reporting and Surveillance

Science and Technology

Clinical Characteristics of 26 Human Cases of Highly Pathogenic Avian Influenza A (H5N1) Virus Infection in China
8/25/08 PLoS--While human cases of highly pathogenic avian influenza A (H5N1) virus infection continue to increase globally, available clinical data on H5N1 cases are limited. We conducted a retrospective study of 26 confirmed human H5N1 cases identified through surveillance in China from October 2005 through April 2008.
AI Research

Univ. of Pittsburgh scientists receive $3.6M to test vaccine against deadliest strain of avian flu
8/25/08 Univ. of Pittsburgh--Scientists at the University of Pittsburgh Center for Vaccine Research have been awarded $3.6 million from the National Institute of Allergy and Infectious Diseases to conduct animal studies of vaccines designed to protect against the most common and deadliest strain of avian flu, H5N1. Recent outbreaks of H5N1 have prompted health officials to warn of its continued threat to global health and potential to trigger an avian flu pandemic.
Vaccines

H1N1 flu viruses growing more resistant to Tamiflu
8/25/08 CIDRAP--With influenza season well under way in the southern hemisphere, one of the three kinds of seasonal influenza virus is becoming increasingly resistant to the antiviral drug oseltamivir (Tamiflu), the World Health Organization (WHO) reported last week.
Antivirals

Protein Structure Discovery Opens Door For Drugs To Fight Bird Flu, Other Influenza Epidemics
8/25/08 ScienceDaily--Researchers at Rutgers University and The University of Texas at Austin have reported a discovery that could help scientists develop drugs to fight the much-feared bird flu and other virulent strains of influenza.
AI Research

Novavax Says Vaccine Protects Humans Against Deadly Bird Flu
8/26/08 Bloomberg--Novavax Inc. said its experimental vaccine spurred an immune response in humans that can protect against a deadly strain of bird flu linked to more than 100 deaths.
Vaccines


Full Text of Articles follow ...


AI Research

Clinical Characteristics of 26 Human Cases of Highly Pathogenic Avian Influenza A (H5N1) Virus Infection in China


Hongjie Yu1#, Zhancheng Gao2#*, Zijian Feng1#, Yuelong Shu3#, Nijuan Xiang1, Lei Zhou1, Yang Huai1, Luzhao Feng1, Zhibin Peng1, Zhongjie Li1, Cuiling Xu3, Junhua Li4, Chengping Hu5, Qun Li6, Xiaoling Xu7, Xuecheng Liu8, Zigui Liu9, Longshan Xu10, Yusheng Chen11, Huiming Luo12, Liping Wei13, Xianfeng Zhang14, Jianbao Xin15, Junqiao Guo16, Qiuyue Wang17, Zhengan Yuan18, Longnv Zhou19, Kunzhao Zhang20, Wei Zhang21, Jinye Yang22, Xiaoning Zhong23, Shichang Xia24, Lanjuan Li25, Jinquan Cheng26, Erdang Ma27, Pingping He28, Shui Shan Lee29, Yu Wang1, Timothy M. Uyeki30, Weizhong Yang1*

1 Office for Disease Control and Emergency Response, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China, 2 Department of Respiratory Medicine, Peking University People's Hospital, Beijing, China, 3 State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China, 4 Hunan Provincial Center for Disease Control and Prevention, Changsha, China, 5 Xiang Ya Hospital of Central South University, Changsha, China, 6 Anhui Provincial Center for Disease Control and Prevention, Hefei, China, 7 Anhui Provincial Hospital, Hefei, China, 8 Sichuan Provincial Center for Disease Control and Prevention, Chengdu, China, 9 Huaxi Hospital, Sichuan University, Chengdu, China, 10 Fujian Provincial Center for Disease Control and Prevention, Fuzhou, China, 11 Fujian Provincial Hospital, Fuzhou, China, 12 Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China, 13 Third Affiliated Hospital, Guangzhou Medical College, Guangzhou, China, 14 Hubei Provincial Center for Disease Control and Prevention, Wuhan, China, 15 Hankou Union Hospital, Hubei Province, Wuhan, China, 16 Liaoning Provincial Center for Disease Control and Prevention, Shenyang, China, 17 First Affiliated Hospital, China Medical University, Shenyang, China, 18 Shanghai Center for Disease Control and Prevention, Shanghai, China, 19 Ninth Affiliated Hospital, Shanghai Transportation University, Shanghai, China, 20 Jiangxi Provincial Center for Disease Control and Prevention, Nanchang, China, 21 First Affiliated Hospital, Nanchang University, Nanchang, China, 22 Guangxi Provincial Center for Disease Control and Prevention, Nanning, China, 23 First Affiliated Hospital, Guangxi Medical University, Nanning, China, 24 Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China, 25 First Affiliated Hospital, Zhejiang University, Hangzhou, China, 26 Shenzhen Center for Disease Control and Prevention, Shenzhen, China, 27 Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention, Urumqi, China, 28 Department of Epidemiology and Biostatistics School of Public Health, Health Science Center, Peking University, Beijing, China, 29 Centre for Emerging Infectious Diseases, Chinese University of Hong Kong, Hong Kong Special Administrative Region, China, 30 Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

Abstract

Background

While human cases of highly pathogenic avian influenza A (H5N1) virus infection continue to increase globally, available clinical data on H5N1 cases are limited. We conducted a retrospective study of 26 confirmed human H5N1 cases identified through surveillance in China from October 2005 through April 2008.

Methodology/Principal Findings

Data were collected from hospital medical records of H5N1 cases and analyzed. The median age was 29 years (range 6?62) and 58% were female. Many H5N1 cases reported fever (92%) and cough (58%) at illness onset, and had lower respiratory findings of tachypnea and dyspnea at admission. All cases progressed rapidly to bilateral pneumonia. Clinical complications included acute respiratory distress syndrome (ARDS, 81%), cardiac failure (50%), elevated aminotransaminases (43%), and renal dysfunction (17%). Fatal cases had a lower median nadir platelet count (64.5×109 cells/L vs 93.0×109 cells/L, p = 0.02), higher median peak lactic dehydrogenase (LDH) level (1982.5 U/L vs 1230.0 U/L, p = 0.001), higher percentage of ARDS (94% [n = 16] vs 56% [n = 5], p = 0.034) and more frequent cardiac failure (71% [n = 12] vs 11% [n = 1], p = 0.011) than nonfatal cases. A higher proportion of patients who received antiviral drugs survived compared to untreated (67% [8/12] vs 7% [1/14], p = 0.003).

Conclusions/Significance

The clinical course of Chinese H5N1 cases is characterized by fever and cough initially, with rapid progression to lower respiratory disease. Decreased platelet count, elevated LDH level, ARDS and cardiac failure were associated with fatal outcomes. Clinical management of H5N1 cases should be standardized in China to include early antiviral treatment for suspected H5N1 cases.

Citation: Yu H, Gao Z, Feng Z, Shu Y, Xiang N, et al. (2008) Clinical Characteristics of 26 Human Cases of Highly Pathogenic Avian Influenza A (H5N1) Virus Infection in China. PLoS ONE 3(8): e2985. doi:10.1371/journal.pone.0002985

Editor: Joel Mark Montgomery, U.S. Naval Medical Research Center Detachment/Centers for Disease Control, United States of America

Received: January 24, 2008; Accepted: July 19, 2008; Published: August 21, 2008

This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.

Funding: This study was supported by grants from the Ministry of Science and Technology of China (2004BA519A17, 2004BA519A71 and 2006BAD06A02), and the China-U.S. Collaborative Program on Emerging and Re-emerging Infectious Diseases. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

* E-mail: gaozhancheng5446@163.com (ZG); yangwz@chinacdc.cn (WY)

# These authors contributed equally to this work.
Introduction

As of July 13, 2008, 385 confirmed human cases of infection with highly pathogenic avian influenza A (H5N1) virus with 243 deaths had been reported from 15 countries since November, 2003 [1]. Although largely a panzoonotic among poultry and wild birds, avian-to-human transmission of H5N1 virus has resulted in most human cases [2], with rare instances of limited, non-sustained human-to-human H5N1 virus transmission [3]?[5]. The continuing propagation of highly pathogenic H5N1 viruses among poultry [6] and migratory birds [7], [8] poses a continuing and potentially escalating threat to human populations. Preparedness for a possible H5N1 pandemic requires not only enhanced prevention efforts but also a heightened awareness of the clinical characteristics of H5N1 cases among physicians.

To date, limited H5N1 clinical data are available in case reports and limited case series from Hong Kong Special Administrative Region (SAR), China in 1997 [9] and 2003 [10], and Vietnam [11], [12], Thailand [13]?[15], Indonesia [4], [16], Cambodia [17], Azerbaijan [18], [19], and Turkey [20] during 2004?2006. These observational studies described symptoms, signs, and laboratory findings at hospital admission. Few data are available on the clinical characteristics of cases throughout the course of H5N1 disease. Data on the natural history of H5N1 disease may allow risk stratification and identification of prognostic factors for outcomes of H5N1 virus infection. We describe the natural history and report the clinical characteristics at illness onset, hospital admission, and throughout hospitalization for 26 H5N1 cases identified by surveillance between October 2005 and April 2008.
Methods
National surveillance system and case definitions

In China, all suspected H5N1 cases are reported to the Chinese Center for Disease Control and Prevention (China CDC, Beijing, China) through a national surveillance system, which is based upon reporting of hospitalized cases of pneumonia of unknown origin, and by enhanced 1-month surveillance for cases of influenza-like illness at all health-care facilities within a 3-km radius after the occurrence of a suspected or confirmed H5N1 poultry outbreak with high bird mortality.

A case of pneumonia of unknown origin was defined as a patient with all of the following criteria without specific laboratory diagnosis: fever (temperature ?38°C); radiological evidence of pneumonia or acute respiratory distress syndrome (ARDS); normal white blood cell count (WBC; range 4?10×109 cells per L), leukopenia (WBC <4×109 cells per L), or lymphopenia (lymphocyte count <0.8×109 cells per L) at clinical presentation; and absence of clinical improvement after treatment with broad-spectrum antibiotics. A case of influenza-like illness was defined as a patient with fever (temperature ?38°C) and cough or sore throat, in the absence of any other confirmed diagnosis.

A confirmed case of H5N1 was defined as a patient with pneumonia or influenza-like illness and laboratory evidence of H5N1 virus infection diagnosed by viral isolation or reverse transcriptase (RT) PCR by testing respiratory specimens, or a four-fold or greater increase in H5N1 antibody titre in paired acute and convalescent sera.
Case-patients

All suspected H5N1 case-patients were interviewed by staff of the local CDC, and respiratory specimens, and acute- and convalescent-phase sera were obtained if available for laboratory investigations following the WHO protocol [21]. Respiratory specimens were tested by conventional [22] and real-time RT-PCR [23] to detect H5-specific viral RNA in biosafety level (BSL) 2 facilities at the National Influenza Center (NIC) of China CDC, and were inoculated into amniotic and/or allantoic cavities of specific pathogen free (SPF) embryonated chicken eggs for viral isolation [24] in enhanced BSL 3 facilities at the NIC. H5N1 antibody testing was performed on sera at the NIC by microneutralization (MN) assay [25] in a BSL-3 laboratory, and modified hemagglutination-inhibition (HI) assay using horse red blood cells [26] in BSL-2 conditions.

In mainland China, 30 confirmed human H5N1 cases have been identified to date. We included 26 laboratory-confirmed H5N1 cases identified by surveillance in 12 provinces in China between October 2005 and April 2008. Our analyses included limited data from 2 case reports [27], [28] and 6 urban cases reported previously in a brief epidemiological dispatch [29]. Of the 26 cases, H5N1 virus infection was confirmed by both virus isolation and RT-PCR in 20 (77%) cases, one (4%) case by virus isolation only, three (11%) by RT-PCR and serology, and two (8%) by serology only. Twenty-four cases in southern China were infected with clade 2.3.4 H5N1 viruses, and two cases from northern China had clade 2.2 H5N1 virus infections [2]. We excluded four H5N1 cases, including 2 military cases with unavailable clinical data and 2 cases in a cluster with limited person-to-person transmission reported elsewhere [5].
Clinical investigations

A trained team from the China CDC interviewed all confirmed H5N1 cases or their proxies, and collected clinical data through review of hospital medical records. A standardized form was used to collect information on demographic characteristics and clinical data, including clinical findings, blood chemistry testing and chest radiograph results performed during clinical management, complications, treatments, and outcomes. Data were collected during field investigations by China CDC staff, and was part of a continuing public-health outbreak investigation and determined by the Ministry of Health to be exempt from institutional review board assessment in China.

We used the following definitions: cardiac failure was defined as requiring use of inotropic agents; respiratory failure was defined as the need for assisted ventilatiory support; ARDS was defined as clinical deterioration with severe arterial hypoxaemia and diffuse bilateral infiltrates on chest radiograph; disseminated intravenous coagulation (DIC) was defined as elevated prothrombin time (PT) with elevated activated partial thromboplastin time (APTT), and decreased fibrinogen (FIB) level with thrombocytopenia; liver function impairment was defined as aminotransferase (ALT or AST) levels ? 2× upper range of normal values; renal dysfunction was defined as creatinine level >178mmol/L for adults or ? 2× upper limit of normal for age. High-dose corticosteroid use was defined as ?250 mg hydrocortisone or equivalent intravenous (IV) administration daily. For children <13 years old, high-dose corticosteroid use was defined as ?5 mg hydrocortisone or equivalent IV/kg/day.
Statistical analysis

Medians and interquartile ranges (IQRs) were calculated for continuous variables, and compared between fatal and nonfatal cases using Wilcoxon rank sum test. For categorical variables, percentages of case-patients in each category were compared using Fisher's exact test. Fatal cases were compared to nonfatal cases by demographic characteristics, H5N1 virus clade, underlying medical conditions, medical care practices, haematological and biochemical markers at admission or during hospitalization, clinical complications, and treatments, in the bivariate analyses using logistic regression. All statistical tests were two-sided with a significance level set at ? = 0.05. Data were analyzed with SPSS (version 13.0, SPSS Inc, Chicago, IL, USA).
Results

Twenty-six confirmed H5N1 cases had illness onset beginning in October, 2005 through February 2008. The median age of the 26 cases was 29 years (range 6?62) and 58% were female. Five (19%) were children aged <10 years old, one (4%) was 16 years old, and 20 (77%) were adults aged >18 years.
Clinical presentation

The earliest reported symptoms and signs of 26 patients at illness onset and noted at hospital admission are shown in Table 1. Many patients reported fever (92%) or cough (58%) initially, but very few reported upper respiratory symptoms such as rhinorrhea or sore throat. All patients developed cough a median of 1 day (IQR 1?3) from illness onset, and 85% had sputum production a median of 3 days (IQR 1?5.3) after illness onset. Lower respiratory tract signs and symptoms such as tachypnea and dyspnea increased substantially from illness onset to hospital admission. Most patients (88%) had tachypnea a median of 5 days (IQR 4?7) from illness onset and 46% reported dyspnea a median of 6.5 days (IQR 4.5?8.5) from illness onset. Diarrhea was reported in only one adult case at illness onset, and in two cases at hospital admission, but developed in six patients (one child and five adults) after hospitalization. The duration of diarrhea in these nine (35%) cases was a median of 1 day (IQR 1?4).
thumbnail

Table 1. Signs and symptoms of 26 H5N1 cases at illness onset and at hospital admission, China.
doi:10.1371/journal.pone.0002985.t001

All case-patients had abnormal chest radiographs at admission; unilateral or bilateral infiltrates were observed in 10 (38%) and 16 (62%) case-patients, at a median of 6.5 days (IQR 4?7.3) and 7.5 days (IQR 6.3?9) from illness onset, respectively. The 10 case-patients with unilateral infiltrates at admission all developed bilateral pneumonia (Table 2). Chest radiographs showing rapid progression from unilateral to bilateral pulmonary infiltrates and ARDS in adult and paediatric cases are shown in Figure 1. Radiographic findings included patchy or diffuse infiltrates or consolidation with air bronchograms in multi-segmental or lobular distribution.
thumbnail

Figure 1. Progression of pulmonary disease in chest radiographs from adult (35-year-old male, Panels A day 6 and B day 23 of illness) and pediatric (6-year-old male, Panels C day 6 and D day 14 of illness) H5N1 cases.
doi:10.1371/journal.pone.0002985.g001
thumbnail

Table 2. Initial chest radiographic findings and progression during hospitalization of 26 H5N1 cases, China.
doi:10.1371/journal.pone.0002985.t002
Laboratory findings

Laboratory findings on initial testing, at admission and during hospitalization are shown in Table 3. The prevalence of patients with abnormal haematological findings at admission [leukopenia (46%), lymphopenia (62%), and moderate thrombocytopenia (50%)] increased to 92%, 89% and 73%, respectively, during hospitalization. At admission, the median leukocyte count was 3.5×109 cells/L (IQR 2.3?4.5) and median lymphocyte count was 0.6×109 cells/L (IQR 0.4?1.0). These declined during hospitalization to a median leukocyte count of 2.3×109 cells/L (IQR 1.5?2.8) and median lymphocyte count of 0.3×109 cells/L (IQR 0.3?0.5), after a median of 8.0 days.
thumbnail

Table 3. Laboratory findings of 26 H5N1 cases* on initial testing, at hospital admission, and during hospitalization, China.
doi:10.1371/journal.pone.0002985.t003

Abnormal percentage, peak measurement and median days from illness onset of biochemical markers on initial testing, at hospital admission, and during hospitalization are shown in Table 3. Elevated ALT, AST, creatine kinase (CK), creatine phosphokinase isoenzymes (CPK), lactic dehydrogenase (LDH), and plasma glucose concentration, and decreased albumin levels were observed in more than half of cases at admission, and developed in nearly all cases during hospitalization. Elevated creatine level was observed in 25% of cases during hospitalization. Seventeen (77%) cases developed proteinuria at a median of 9.0 days (IQR 7.0?11) after illness onset.
Treatment

All cases received empiric treatment with broad-spectrum antibiotics during hospitalization, including ceftriaxone (n = 6), moxifloxacin (n = 8) and azithromycin (n = 15). Corticosteroids (median methylprednisolone dosage 1.6 [1]?[5] mg/kg per day IV) were initiated at a median of 6.5 days (IQR 6.0?8.0) from illness onset and administered to 24 (92%) cases for a median of 6 days (IQR 3?13). Of these, 21 (88%) received high-dose corticosteroids.

Four children received late antiviral treatment. One was treated with amantadine (100 mg per os (po) twice daily (BID) on illness days 10?15) and ribavirin (200 mg IV/d on illness days 9?16), and one received rimantadine (100 mg po each day (qD) on illness days 9?11); both cases survived. One child received oseltamivir (37.5 mg po BID) on illness days 12?14, and one child was treated with oseltamivir (40 mg po qD) on illness day 10; both died. Eight adults received late oseltamivir treatment, including two fatal cases ? one received 75 mg po BID on illness days 8?11, and one received both oseltamivir (75mg po BID on illness days 11?20) and rimantadine (200mg po qD on illness day 11). Six adults treated with oseltamivir survived: one was treated with 75 mg/day on illness days 8?12, four received 75 mg BID on illness days 4?11, illness days 8?14, illness days 10?14, and illness days 8?12, respectively, and one was treated with 75mg BID and amantadine (100 mg po BID) on illness days 8?12.

Two critically ill adult H5N1 cases (31-year-old male, 44-year-old female) with ARDS were treated with convalescent plasma obtained from one of two fully recovered H5N1 adult donor cases. Plasma was obtained 129 days after illness onset from an adult female case and 81 days after illness onset from an adult male case. Both donors' convalescent plasma tested negative for hepatitis B, hepatitis C, and HIV, and were separated and heat-inactivated at 56°C for 10 h before transfusion. The male ARDS case received three units (200 mL/unit) of transfused convalescent plasma from the female donor for 2 days, beginning on illness day 13. His H5N1 viral titre in bronchial-alveolar lavage fluid declined substantially and was undetectable for the next 3 consecutive days after receipt of the third convalescent plasma dose. The female ARDS case, who had a history of bronchiectasis, received one unit (200 mL) of transfused convalescent plasma from the male donor once daily for 3 days, starting on illness day 13. Further virological testing has not been done for this case. Both cases also received oseltamivir (75 mg po BID) on illness days 10?14 and days 8?12, respectively. Both cases recovered fully and were discharged home.
Complications and outcomes

Twenty-three (88%) cases required ventilatory support for respiratory failure. ARDS developed in 21 (81%) cases at a median of 8 days (IQR 7?9) after illness onset. Liver function impairment, renal dysfunction and cardiac failure occurred in 9 (43%), 4 (17%) and 13 (50%) patients.

Seventeen (65%) cases died (2 children, 1 adolescent and 14 adults), including one pregnant woman at 4 months' gestation [28] after a median of 10 days (IQR 8?20.5). Nine (35%) nonfatal cases were discharged at a median of 41 days (IQR 31.5?64.0) after illness onset. Five (24%) of the 21 cases with ARDS survived, including one pregnant woman, two adults who received convalescent H5N1 plasma, and two other previously healthy adults. The pregnant woman survived after developing ARDS and experiencing a spontaneous abortion during mechanical ventilation. Her pulmonary status subsequently improved and her temperature normalised quickly; the patient was extubated and recovered completely. All 17 fatal cases had multi-organ failure, including respiratory failure (94%), cardiac failure (71%), renal failure (27%) and 24% had disseminated intravenous coagulation (Table 4).
thumbnail

Table 4. Comparison of demographic and clinical features of 17 fatal and 9 nonfatal H5N1 cases, China.
doi:10.1371/journal.pone.0002985.t004

In the bivariate analyses, demographic characteristics, year of illness onset, clade of H5N1 virus infection, and underlying medical conditions were similar between fatal and nonfatal cases (Table 4). Fatal cases had significantly lower median nadir platelet count during hospitalization (64.5×109 cells/L vs 93.0×109 cells/L, p = 0.02), higher median peak LDH level during hospitalization (1982.5 U/L vs 1230.0 U/L, p = 0.001), higher frequency of ARDS (94% [n = 16] vs 56% [5], p = 0.034), more frequent cardiac failure (71% [n = 12] vs 11% [1], p = 0.011), and shorter median duration of corticosteroid therapy (4.0 days vs 12.0 days, p = 0.025) compared to cases that survived. A higher proportion of cases survived that received any antiviral treatment compared to those that did not receive antivirals (67% [8/12 patients] vs 7% [1/14 patients], p = 0.003), with a positive correlation between antiviral therapy and disease outcome (Gamma coefficient = 0.664, p = 0.005).
Discussion

Our findings suggest that H5N1 disease in Chinese patients generally begins with fever, cough, and sputum production, and progresses rapidly to lower respiratory disease. Upper respiratory symptoms of rhinorrhea and sore throat were less common in China than observed in Hong Kong SAR, China [9], Thailand [13], Turkey [21], Azerbaijan [18], and Egypt [2]. Studies suggest that the lower respiratory tract is the major site for H5N1 viral replication, although initial infection may occur in either the upper or lower respiratory tract [30]?[33].

Diarrhea was present in only two H5N1 cases at admission, but developed in a quarter of cases during hospitalization. Diarrhea was a common presenting symptom among H5N1 cases in Vietnam [11], [12] and Thailand [13], but was reported infrequently among cases in Hong Kong SAR, China [9], [10], and Indonesia [4], [16]. H5N1 virus and viral RNA have been detected in feces and intestines of human H5N1 cases [12], [17], [30], [33]. Whether the gastrointestinal tract is a primary site for H5N1 virus infection is currently unknown.

Disease course in Chinese H5N1 cases was rapidly progressive; the median time from illness onset to death in our case series is consistent with WHO findings [2]. All H5N1 cases presented with pulmonary infiltrates, and all cases progressed rapidly to bilateral disease. Many cases experienced respiratory failure, ARDS, and multi-organ failure, with hepatic dysfunction and cardiac failure. Leukopenia and lymphopenia were also common. A recent molecular pathology study on two cases documented that in addition to the lungs, H5N1 virus infects the trachea and disseminates to other organs including the brain [30]. Our findings are consistent with other reports [11]?[20]. The pathogenesis of some clinical complications could be immunologically mediated, as suggested by high levels of proinflammatory cytokines and chemokines in vitro and cytokine dysregulation in fatal cases in observational studies [10], [33], [34].

Five H5N1 cases were younger than 10 years old and one was aged 16-years, in contrast to other case series [16], [19]?[20] and the WHO finding that the highest frequency of cases was aged 10?19 years old [35]. The age profile of Chinese H5N1 cases may reflect exposure differences due to traditional social and cultural behaviours. Visiting wet poultry markets in urban areas and exposure to sick or dead backyard poultry in rural areas before illness onset are H5N1 risk factors in China (unpublished data, China CDC). Paediatric cases lived in rural areas of China, and likely had more exposures to sick/dead backyard poultry than children in urban areas. In rural areas, young Chinese children are much more likely to play with backyard poultry than older children. Adults are much more likely to visit poultry markets in urban areas of China than children and all urban adult H5N1 cases had visited a wet poultry market prior to illness onset (unpublished data, China CDC).

In contrast to the WHO finding that cases aged 10?19 years old had the highest case-fatality [2], mortality of H5N1 cases in China was not associated with median age, sex or underlying medical conditions in the bivariate analysis. Isolates from 24 cases in southern China were characterized as H5N1 clade 2.3.4 viruses with consistent genetic and antigenic properties from 2005 through 2008 (unpublished data, China CDC). There were no significant differences in case-fatality ratios between years during 2005?2008 or between cases with clade 2.2 and clade 2.3.4 H5N1 virus infection. However, fatal outcomes were associated with decreased platelet counts, increased LDH, ARDS, cardiac failure, and lack of antiviral treatment in the bivariate analyses. In Thailand [13] and Hong Kong SAR [9], mortality was associated with late presentation, lower admission leukocyte, platelet, and lymphocyte counts, bilateral pulmonary findings on chest X-ray, and development of ARDS. Decreased leukocyte and lymphocyte counts, and increased d-dimer levels were associated with fatal outcomes in other studies [4], [17], [20], [33].

Survival was significantly higher in cases that received any antiviral treatment than in untreated cases, and 5 of 8 adult cases that received standard oseltamivir treatment survived even though all were treated late in their illnesses. However, it should be noted that treatment was uncontrolled and our findings lack sequential virological data on antiviral susceptibilities or quantitative H5N1 viral shedding, and favorable outcomes and clinical courses of some H5N1 cases cannot be attributed definitively to antiviral treatment. In contrast to clade 1 H5N1 viruses isolated in Vietnam and clade 2.1 viruses in Indonesia [2], the clade 2.3.4 and clade 2.2 H5N1 viruses isolated from cases in China were susceptible to both M2 inhibitors and neuraminidase inhibitors (unpublished data, China CDC). These findings suggest roles for either class of antiviral drugs as well as combination antiviral therapy for H5N1 cases in China [36], [37].

Very few Chinese H5N1 cases received early antiviral treatment because only one patient was admitted within two days of illness onset, and no patients received outpatient antiviral treatment. Antivirals were not administrated to most Chinese H5N1 cases until they were hospitalized with pneumonia. Oseltamivir was not available in some hospitals for treatment of some cases that died. Therefore, education of health-care providers about the epidemiological risk factors and clinical characteristics of H5N1 patients, and wider availability of antiviral drugs could help facilitate earlier detection and treatment of H5N1 cases in China. Although little data on early versus late oseltamivir treatment for H5N1 patients are available, current WHO guidance recommends initiating oseltamivir treatment as early as possible, including consideration of higher dosing for severe disease and longer treatment duration because of prolonged viral replication [37].

Although antiviral therapy is the primary treatment, most clinical management of H5N1 disease is supportive. For severely ill Chinese H5N1 patients with ARDS or multiorgan failure, management has focused on appropriate mechanical ventilation, correction of hypoxemia, fluid management, and treatment of other complications such as DIC. Corticosteroids were administered empirically to most H5N1 cases in China. A reduction in the proportion of cases reporting with fever from illness onset (92%) to hospital admission (69%) may reflect an early use of corticosteroids or non steroidal anti-inflammatory drugs. Compared to fatal cases, nonfatal cases in China had a longer duration of corticosteroid treatment. However, we cannot conclude that corticosteroid therapy resulted in survival and such treatment has not been shown to be effective in H5N1 patients [2]. Furthermore, prolonged or high-dose corticosteroid therapy may result in serious adverse events, including infection with opportunistic pathogens. Recent WHO H5N1 treatment guidance recommends against routine use of corticosteroid treatment [37].

Two cases with ARDS survived after receiving passive immunotherapy with transfused convalescent plasma from surviving H5N1 cases. This is compelling, but since passive immunotherapy and other treatments were administered in an uncontrolled manner, no definitive conclusions can be made about the benefit of such treatment [38]. A third Chinese H5N1 case survived after receiving post-vaccination plasma from an H5N1 vaccine clinical trial participant and combination antiviral treatment [5]. A meta-analysis of studies of convalescent plasma treatment during the 1918 influenza pandemic [39], evidence from animal experiments [40]?[42], and the limited experience in three Chinese H5N1 cases suggest that passive immunotherapy may be a viable option for the treatment of H5N1. Further research is needed to investigate the efficacy and effectiveness of passive immunotherapy with H5N1 convalescent plasma treatment for H5N1 patients, including cases with severe complications such as ARDS.

Our study was limited to available data for H5N1 cases identified through surveillance during the study period. Due to the small number of H5N1 cases, the study was too underpowered to compare differences between fatal and nonfatal cases. National surveillance and laboratory testing might not have identified all H5N1 cases that occurred, especially if the cases were clinically mild. Clinical management was uncontrolled, H5N1 viral shedding data, immunological and pathological data were not available, and any differences in outcomes cannot be interpreted to be due to the use of antiviral drugs, corticosteroids, or other uncontrolled treatments.

To improve clinical management of H5N1 patients in China, physicians should be educated about the natural history of H5N1 disease and epidemiological risk factors, and therapy should be standardized based upon current knowledge [37]. Early antiviral treatment and expanded testing should be considered for suspected H5N1 patients, with wider availability of antiviral medications at all health care facilities. In the absence of any definitive treatment for H5N1, preventive education to reduce risk behaviours for H5N1 exposures (e.g. avoiding direct contact with sick or dead poultry) must be emphasized more strongly.
Acknowledgments

We thank the provincial health bureaus of Hunan, Anhui, Sichuan, Fujian, Guangdong, Hubei, Liaoning, Shanghai, Jiangxi, Guangxi, Zhejiang and Xinjiang for assistance in coordinating field investigations and provision logistics support, and the Ministry of Health in China for generously facilitating this study. We thank Chin-Kei Lee from the WHO Beijing Office for helping us prepare the article. The views expressed in this article are those of the authors and do not represent the official policy of the China CDC or US CDC.

Author Contributions
Wrote the paper: HY TU. Designed the protocal of investigation, set up the field clinical investigation, contacted all investigators: HY ZG ZF YS WY. Responsible for the virus isolation, microneutralisation, hemagglutination inhibition assay, RT PCR, and real-time RT PCR testing, including the experimental design and analysis of data: YS CX. Participated in collection and management of data: NX LZ YH LF ZP ZL JL CH QL XX XL ZL LX YC HL LW XZ JX JG QW ZY LZ KZ WZ JY XZ SX LL JC EM PH SSL YW. Provided technical assistance for the clinical investigations and helped to review the data: TU.
References

1. World Health Organization. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. Available: http://www.who.int/csr/disease/avian_influenza/country/cases_table_2008_06_19/en/index.html via the Internet. Accessed July 13, 2008.
2. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus (2008) Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 358: 261?273. Find this article online
3. Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, et al. (2005) Probable person-to-person transmission of avian influenza A(H5N1). N Engl J Med 352: 333?340. Find this article online
4. Kandun IN, Wibisono H, Sedyaningsih ER, Yusharmen, Hadisoedarsuno W, et al. (2006) Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med 355: 2186?2194. Find this article online
5. Wang H, Feng Z, Shu Y, Yu H, Zhou L, et al. (2008) Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet 371: 1427?1434. Find this article online
6. World Organisation for Animal Health. Update on avian influenza in animals (type H5). Available: http://www.oie.int/downld/AVIAN20INFLUENZA/A_AI-Asia.htm via Internet. Accessed May 20, 2008.
7. Liu J, Xiao H, Lei F, Zhu Q, Qin K, et al. (2005) Highly pathogenic H5N1 influenza virus infection in migratory birds. Science 309: 1206. Find this article online
8. Chen H, Smith GJ, Zhang SY, Qin K, Wang J, et al. (2005) Avian flu: H5N1 virus outbreak in migratory waterfowl. Nature 436: 191?192. Find this article online
9. Yuen KY, Chan PKS, Peiris M, Tsang DN, Que TL, et al. (1998) Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 351: 467?471. Find this article online
10. Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, et al. (2004) Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363: 617?619. Find this article online
11. Tran TH, Nguyen TL, Nguyen TD, Luong TS, Pham PM, et al. (2004) Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 350: 1179?1188. Find this article online
12. de Jong MD, Bach VC, Phan TQ, Vo MH, Tran TT, et al. (2005) Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 352: 686?691. Find this article online
13. Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, Chunsuthiwat S, Sawanpanyalert P, et al. (2005) Human disease from influenza A(H5N1), Thailand, 2004. Emerg Infect Dis 11: 201?209. Find this article online
14. Apisarnthanarak A, Kitphati R, Thongphubeth K, Patoomanunt P, Anthanont P, et al. (2004) Atypical avian influenza (H5N1). Emerging Infect Dis 10: 1321?1324. Find this article online
15. Areechokchai D, Jiraphongsa C, Laosiritaworn Y, Hanshaoworakul W, O'Reilly M (2006) Investigation of avian influenza (H5N1) outbreak in humans ? Thailand, 2004. MMWR Morb Mortal Wkly Rep 55: Suppl 13?6. Find this article online
16. Sedyaningsih ER, Isfandari S, Setiawaty V, Rifati L, Harun S, et al. (2007) Epidemiology of Cases of H5N1 Virus Infection in Indonesia, July 2005?June 2006. J Infect Dis 196: 522?527. Find this article online
17. Buchy P, Mardy S, Vong S, Toyoda T, Aubin JT, et al. (2007) Influenza A/H5N1 virus infection in humans in Cambodia. J Clin Virol 39: 164?168. Find this article online
18. Gilsdorf A, Boxall N, Gasimov V, Agayev I, Mammadzade F, et al. (2006) Two clusters of human infection with influenza A/H5N1 virus in the Republic of Azerbaijan, February?March 2006. Euro Surveill 11: Find this article online
19. (2006) Human avian influenza in Azerbaijan, February?March 2006. Wkly Epidemiol Rec 81: 183?188. Find this article online
20. Oner AF, Bay A, Arslan S, Akdeniz H, Sahin HA, et al. (2006) Avian influenza A (H5N1) infection in eastern Turkey in 2006. N Engl J Med 355: 2179?2185. Find this article online
21. World Health Organization. Collecting, preserving and shipping specimens for the diagnosis of avian influenza A(H5N1) virus infection. Guide for field operations. WHO/CSR WEB SITE, 1?51. 2006. Available: http://www.who.int/csr/resources/publications/surveillance/WHO_CDS_EPR_ARO_2006_1/en/via the Internet. Accessed May 20, 2008.
22. World Health Organization. Recommended laboratory tests to identify avian influenza A virus in specimens from humans. http://www.who.int/csr/disease/avain_influenza/guidlines/via the Internet. Accessed May 20, 2008.
23. Spackman E, Senne DA, Myers TJ, Bulaga LL, Garber LP, et al. (2002) Development of a real-time reverse transcriptase PCR assay for type A influenza virus and the avian H5 and H7 hemagglutinin subtypes. J Clin Microbiol 40: 3256?3260. Find this article online
24. (2002) World Health Organization. Manual on animal influenza diagnosis and surveillance, 2002. (WHO/CDS/CSR/NCS/2002.5 Rev. 1). http://www.who.int/vaccine_research/diseases/influenza/WHO_manual_on_animal-diagnosis_and_surveillance_2002_5.pdf via the Internet. Accessed May 20, 2008.
25. World Health Organization. Manual on influenza microneutralization assay. http://www.who.int/csr/disease/avain_influenza/guidlines/via the Internet. Accessed May 20, 2008.
26. Stephesen I, Wood JM, Nicholson KG, Zambon MC (2003) Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin. J Med Virol 70: 391?398. Find this article online
27. Yu H, Shu Y, Hu S, Zhang H, Gao Z, et al. (2006) The first confirmed human case of avian influenza A (H5N1) in Mainland China. Lancet 367: 84. Find this article online
28. Shu Y, Yu H, Li D (2006) Lethal avian influenza A (H5N1) infection in a pregnant woman in Anhui province, China. N Engl J Med 354: 1421?1422. Find this article online
29. Yu H, Feng Z, Zhang X, Xiang N, Huai Y, et al. (2007) Human influenza A(H5N1) cases, urban areas of People's Republic of China, 2005?2006. Emerg Infect Dis 13: 1061?1064. Find this article online
30. Gu J, Xie Z, Gao Z, Liu J, Korteweg C, et al. (2007) H5N1 infection of the respiratory tract and beyond: a molecular pathology study, Lancet 370: 1137?1145. Find this article online
31. Van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, et al. (2006) H5N1 Virus Attachment to Lower Respiratory Tract. Science 312: 399. Find this article online
32. Uiprasertkul M (2007) Apoptosis and Pathogenesis of Avian Influenza A (H5N1) Virus in Humans. Emerg Infect Dis 13: 708?12. Find this article online
33. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, et al. (2006) Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 12: 1203?1207. Find this article online
34. Chan MC, Cheung CY, Chui WH, Tsao SW, Nicholls JM, et al. (2005) Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Repir Res 6: 135. Find this article online
35. (2007) Update: WHO-confirmed human cases of avian influenza A(H5N1) infection, 25 November 2003?24 November 2006. Wkly Epidemiol Rec 82: 41?48. Find this article online
36. Schünemann HJ, Hill SR, Kakad M, Bellamy R, Uyeki TM, et al. (2007) WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 7: 21?31. Find this article online
37. World Health Organization. Clinical management of human infection with avian influenza A (H5N1) virus. Available: http://www.who.int/csr/disease/avian_influenza/guidelines/clinicalmanage07/en/index.html via the Internet. Accessed May 20, 2008.
38. Zhou B, Zhong N, Guan Y (2007) Treatment with convalescent Plasma for Influenza A (H5N1) Infection, N Engl J Med 357: 1450?1451. Find this article online
39. Luke TC, Kilbane EM, Jackson JL, Hoffman SL (2006) Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment? Ann Intern Med 145: 599?609. Find this article online
40. Lu J, Guo Z, Pan X, Wang G, Zhang D, et al. (2006) Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice. Respir Res 7: 43. Find this article online
41. Hanson BJ, Boon AC, Lim AP, Webb A, Ooi EE, et al. (2006) Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res 7: 126. Find this article online
42. Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, et al. (2007) Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 4(5): e178. Find this article online

Vaccines

Univ. of Pittsburgh scientists receive $3.6M to test vaccine against deadliest strain of avian flu


8/25/08 Univ. of Pittsburgh--Scientists at the University of Pittsburgh Center for Vaccine Research have been awarded $3.6 million from the National Institute of Allergy and Infectious Diseases to conduct animal studies of vaccines designed to protect against the most common and deadliest strain of avian flu, H5N1. Recent outbreaks of H5N1 have prompted health officials to warn of its continued threat to global health and potential to trigger an avian flu pandemic.

"Worldwide avian flu control efforts have been mostly successful, but like seasonal influenza, avian flu changes year to year, creating new subtypes and strains that could easily and quickly spread among humans," said Ted M. Ross, Ph.D., principal investigator of the grant and assistant professor, Center for Vaccine Research, University of Pittsburgh.

Unlike other avian flu vaccines, which are partially developed from live viruses, the vaccines Dr. Ross and colleagues will test in non-human primates are based on a virus-like particle, or VLP, that is recognized by the immune system as a real virus but lacks genetic information to reproduce, making it a potentially safer alternative for a human vaccine. Given the evolving nature of H5N1, the vaccines have been engineered to encode genes for many influenza viral proteins to offer enhanced protection against possible new strains of the virus.

"VLPs may be advantageous over other vaccine strategies because they are easy to develop, produce and manufacture," said Dr. Ross. "Using recombinant technologies, within ten weeks, we could generate a vaccine most effective towards the current circulating strain of virus, making it a cost-effective counter-measure to the threat of an avian influenza pandemic."

###

Co-investigators at the University of Pittsburgh include Simon M. Barratt-Boyes, Ph.D., Department of Infectious Diseases and Microbiology; Gerard J. Nau, M.D., Ph.D. and Jodi K. Craigo, Ph.D., Department of Microbiology and Molecular Genetics; Elodie Ghedin, Ph.D., Department of Medicine; and Clayton A. Wiley, M.D., Department of Pathology.

The Center for Vaccine Research (CVR) at the University of Pittsburgh houses both the Regional Biocontainment Laboratory and the Vaccine Research Laboratory. Researchers at the CVR, directed by Donald S. Burke, M.D., dean of the University of Pittsburgh Graduate School of Public Health and UPMC Jonas Salk Professor of Global Health, develop new methods and strategies to prevent and treat infectious diseases, potentially improving and protecting global health.

Regional Reporting and Surveillance

Sierra Leone: Health Ministry on Bird Flu


8/25/08 Sierra Leone News--The Ministry of Health and Sanitation and security personnel along the border chiefdoms in the Kenema District held a one-day Health Education Division Sensitization meeting for personnel in cross border districts on Avian Flu (Bird Flu).

The consultative meeting took place at the Kenema district council hall along Maxwell Khobe Street in Kenema city. Speaking at the opening ceremony, Manager of Health Education Division Sahr Hemon said the Education Division of the Ministry is meant to educate people about epidemic in various areas.
?The Ministry,? he disclosed, ?is the forerunner in making sure that the epidemic is not spread in the locality.?
Hemon stated that they are calling on people to empower them to sensitize their people about disease. He appealed to participants to spread the messages to friends, neighbors and other people of what they are gaining from the meeting.

?Bird Flu has destroyed many farm animals, such as fowls in other parts of Africa,? said Deputy Health Coordinator Lansana Conteh, ?and as such, the meeting was to discuss the ways of preventing the disease in the country.?

Conteh therefore called on police and military personnel at the borders to report any strange disease affecting the community, so that the ministry can intervene quickly.
The Kenema District Medical Officer (DMO), Dr. Yankuba Madina Bah, in his statement said the disease ?is not one man?s business but the business of everybody,? noting that the disease can easily be transferred to human beings. He appealed to participants to disseminate the messages of what they were gaining from the meeting to the public.

Dr. Bah added that they were treating Lassa fever, which comes from rats, in the hospital and most of the patients were from Lower Bambara chiefdom in the Kenema district. He said they are now working with the bodies in minimizing rabies. The sensitization campaign, he said, is all over the World and as such, he pleaded with the coordinator to expand the meeting to somewhere else in the border region.

Antivirals

H1N1 flu viruses growing more resistant to Tamiflu


8/25/08 CIDRAP--With influenza season well under way in the southern hemisphere, one of the three kinds of seasonal influenza virus is becoming increasingly resistant to the antiviral drug oseltamivir (Tamiflu), the World Health Organization (WHO) reported last week.

Thirty-one percent (242 of 788) of influenza A/H1N1 isolates from 16 countries that were tested in recent months carried a mutation associated with oseltamivir resistance, the WHO said. In South Africa, all of the 107 isolates tested had this mutation, known as H274Y, the agency reported.

Other countries and areas that tested 10 or more isolates and found resistance included Australia, 100% (10 of 10 isolates); Ghana, 20% (2 of 10) Hong Kong, 17% (97 of 583); and Chile, 13% (4 of 32 isolates).

The findings strengthen a trend that that was first observed last January in Norway and subsequently in many other countries. Overall for the last quarter of 2007 and the first quarter of this year, 16% (1,182 of 7,528) of tested H1N1 isolates carried the resistance mutation, according to WHO figures. Resistance was found in 35 countries, mostly in the northern hemisphere, including in 12% of tested US isolates and 26% of tested Canadian isolates.

"What we're seeing is the evolution of the resistance gene and the distribution of it throughout the world," said Lance Jennings, a clinical virologist with the Canterbury District Health Board in Christchurch, New Zealand, and chair of the Asia-Pacific Advisory Committee on Influenza, as quoted in an Aug 22 Bloomberg News report.

In South Africa, Terry Besselaar, director of the National Influenza Centre in Johannesburg, said, "The patients are from across the country, so the resistant strain is widespread," according to the Bloomberg report.

The WHO said only 1 of the 107 patients in South Africa was taking oseltamivir, and no unusual clinical features or underlying conditions were found.

No increase in oseltamivir resistance has been reported in the other two types of seasonal flu viruses, A/H3N2 and B. Recent WHO updates have not indicated which types are most common overall in the southern hemisphere this season, but the Aug 20 statement said flu was widespread in New Zealand, with H3 and B viruses predominant. The statement also cited sporadic flu activity in Argentina, with H1 viruses most common.

Many countries have stockpiled oseltamivir, which is used to treat people infected with the H5N1 avian flu virus and is generally considered the most promising antiviral to use in case H5N1 evolves into a human pandemic strain. The WHO statement did not mention any reports of resistance to zanamivir (Relenza), the other drug in the neuraminidase inhibitor class.

A spokeswoman for Roche, the maker of Tamiflu, said H5N1 viruses remain sensitive to the drug, according to the Bloomberg report. The spokeswoman, Claudia Schmitt, said the company plans to conduct surveillance on resistant and susceptible flu viruses during the 2008-09 flu season.

In a summary of H1N1 resistance to oseltamivir in the the 2007-08 flu season, the WHO said in June that no link between "oseltamivir exposure and resistance at the individual patient level was noted."

The increasing oseltamivir resistance in H1N1 viruses has puzzled experts. In an editorial published by Eurosurveillance in January, authorities said resistant viruses with the H274Y mutation had been seen in previous flu seasons but were rare and did not spread easily. But the more recent H1N1 isolates with the mutation were "fitter" and were spreading in the community, they wrote.

A recent update by the European Centre for Disease Prevention and Control (ECDC) observed, "At this stage the significance of these [resistance] findings remains uncertain. The emergence of drug resistance in the context of limited drug use is unexpected, and the extent of future circulation is difficult to predict."

AI Research

Protein Structure Discovery Opens Door For Drugs To Fight Bird Flu, Other Influenza Epidemics


8/25/08 ScienceDaily--Researchers at Rutgers University and The University of Texas at Austin have reported a discovery that could help scientists develop drugs to fight the much-feared bird flu and other virulent strains of influenza.

The researchers have determined the three-dimensional structure of a site on an influenza A virus protein that binds to one of its human protein targets, thereby suppressing a person's natural defenses to the infection and paving the way for the virus to replicate efficiently. This so-called NS1 virus protein is shared by all influenza A viruses isolated from humans ? including avian influenza, or bird flu, and the 1918 pandemic influenza virus.

A paper detailing this breakthrough discovery appears in the PNAS (Proceedings of the National Academy of Sciences) Early Edition and will be published in an upcoming issue of the PNAS print edition.

About 10 years ago, Professor Robert M. Krug at The University of Texas at Austin discovered that the NS1 protein binds a human protein known as CPSF30, which is important for protecting human cells from flu infection. Once bound to NS1, the human protein can no longer generate molecules needed to suppress flu virus replication. Now, researchers led by Rutgers Professor Gaetano T. Montelione and Krug identified the novel NS1 binding pocket that grasps the human CPSF30 protein.

"Our work uncovers an Achilles heel of influenza A viruses that cause human epidemics and high mortality pandemics," said Montelione, professor of molecular biology and biochemistry. "We have identified the structure of a key target site for drugs that could be developed to effectively combat this disease."

X-ray crystallography, which was carried out by Kalyan Das, Eddy Arnold, LiChung Ma and Montelione, identified the three-dimensional structure of the NS1 binding pocket. "The X-ray crystal structure gives us unique insights into how the NS1 and human protein bind at the atomic level, and how that suppresses a crucial antiviral response," said Das, research professor at Rutgers.

Rei-Lin Kuo, Jesper Marklund, Karen Twu and Krug at The University of Texas at Austin verified the key role of this binding pocket in flu replication by genetically engineering a change to a single amino acid in the NS1 protein's binding pocket, which in turn eliminated the protein's ability to grasp the human protein that is needed to generate antiviral molecules. These investigators then produced a flu virus with an NS1 pocket mutation and showed that this mutated virus does not block host defenses, and as a consequence has a greatly reduced ability to infect human cells.

"These experiments validate the NS1 pocket as a target for antiviral drug discovery," said Krug, professor and chair of molecular genetics and microbiology. "Because this NS1 pocket is highly conserved in all influenza A viruses isolated from humans, a drug targeted to the pocket would be effective against all human influenza A strains, including the bird flu."

This project was supported by two different institutes at the National Institutes of Health (NIH), demonstrating how several NIH initiatives can complement each other. Support for the Rutgers research was provided in part by the Protein Structure Initiative (PSI) of the NIH Institute of General Medical Sciences, a follow-on to the human genome project, which is providing large numbers of protein samples and three-dimensional structures of biologically important proteins to the broad scientific community.

"This work underscores the value of scientific collaborations between large-scale structural centers and individual biomedical research labs," said John Norvell, director of the PSI.

The University of Texas at Austin research was supported by a long-standing grant from the NIH Institute of Allergy and Infectious Disease (NIAID). In addition, NIAID has recently awarded a grant to investigators at The University of Texas at Austin and Rutgers to develop antiviral drugs directed against this NS1 binding pocket.

Other Rutgers faculty members on the research team were James Aramini, Rong Xiao, Li Zhao and Brian Radvansky. Most of the Rutgers investigators are also researchers at the Center for Advanced Biology and Medicine, a joint research institute of Rutgers and the University of Medicine and Dentistry of New Jersey?Robert Wood Johnson Medical School. Krug is also a member of the Institute for Cellular and Molecular Biology at The University of Texas at Austin.

Regional Reporting and Surveillance

Bird flu strain in India, Bangladesh similar


8/25/08 Times of India--The bird flu virus, that caused India's worst Avian Influenza (AI) outbreak this year, has been found to be "a lot similar" to the one that created havoc in Bangladesh.

This has been confirmed by Indian scientists after it studied the genetic make-up of Bangladesh's H5N1 virus strain. India's eastern neighbour, after much persuasion, finally shared the genetic sequencing data of its virus with India earlier this month.

The sequencing was completed in the OIE Reference Laboratory for Avian Influenza in Weybridge, UK. The H5N1 outbreak, that broke out in West Bengal in January this year, spread to nearly 13 of the state's 19 districts.

A animal husbandry department source told TOI: "Both India and Bangladesh finally exchanged genetic information of its H5N1 strains. We have found that both the strains are related. However, we can't say that Bangladesh was the cause of the outbreak in West Bengal because we don't have documented proof to show that infected poultry was smuggled into India."

He added: "We now know that both the viruses was of clade 2.2 variety which is a sub-lineage of the highly pathogenic Qinghai strain. The strain, however, is different to the one that caused the Manipur and Maharashtra outbreaks."

India was almost certain that the virus came from Bangladesh through illegal poultry trade. Even agriculture minister Sharad Pawar had openly said so. The animal husbandry department then made a formal request to the Bangladesh government through the ministry of external affairs to share the genetic history of its virus.

The H5N1 virus was first detected in Bangladesh in March 2007. Since then, over 47 of the country's 64 districts had been affected by bird flu.

Even though Bangladesh reported a human infection, India was lucky on that count and did not see any humans getting infected. The outbreak in Bengal saw over 42 lakh birds being culled.

Sources said that India had also made a formal complaint to FAO and OIE (World Organisation of Animal Health) about Bangladesh's slack handling to contain the virus, seriously putting at risk India's internal security. A team of the Border Security Force, manning the West Bengal-Bangladesh border, had once reported to the Centre how Bangladeshi citizens were seen dumping dead birds in no-man's land.

Vaccines

Novavax Says Vaccine Protects Humans Against Deadly Bird Flu


8/26/08 Bloomberg--Novavax Inc. said its experimental vaccine spurred an immune response in humans that can protect against a deadly strain of bird flu linked to more than 100 deaths.

In the study, 160 patients each received two injections, in doses ranging from 15 to 90 micrograms. At the highest dose, the vaccine produced a response against one version of the lethal H5N1 bird flu in 94 percent of patients, Novavax said in a statement today.

Novavax, based in Rockville, Maryland, has been working with General Electric Co. to develop a vaccine that can be mass- produced quickly. Outbreaks of lethal avian flu have spread from birds to humans in 15 countries, mostly in Asia, and are ``not expected to diminish significantly in the short term,'' according to the U.S. Centers for Disease Control and Prevention's Web site.

``What we've shown in this study is that the vaccine is immunogenic in humans,'' said Rahul Singhvi, Novavax's president and chief executive officer, in an interview. ``It will allow countries around the world to produce a custom vaccine on demand within their own borders.''

Novavax fell 1 cent to $2.97 yesterday in Nasdaq Stock Market composite trading. General Electric fell 80 cents, or 2.8 percent, to $28.32.

There have been 385 confirmed cases of bird flu in humans, resulting in 243 deaths, from late 2003 through June 19 -- the latest data available -- according to the World Health Organization's Web site. The study involved what is known as the Indonesian strain of H5N1. That version has accounted for 135 cases, mostly fatal, of avian flu in humans, according to Novavax.

Insect Cell Cultures

Novavax's process, which uses insect-cell cultures, avoids the need to grow viruses in eggs by making vaccines from particles that mimic viruses. With its process, Novavax can produce seven to 10 times as much vaccine in the same time as techniques that rely on eggs or cells from mammals, the company said. Novavax said it can make vaccine within 10 to 12 weeks of identifying a strain.

``This data milestone marks good progress in the viability of Novavax's vaccine,'' said Peter Ehrenheim, president and chief executive of life sciences for GE Healthcare, based in Chalfont St. Giles, England, near London, in a statement.

Other drug companies, including GlaxoSmithKline Plc and Sanofi-Aventis SA, are developing vaccines that could be produced rapidly during a flu pandemic. Traditional flu shots are made in chicken eggs, a process that can take up to six months after a strain of the virus is identified. Scientists have predicted that an avian flu strain could spread across the globe within days.

Safe to Continue

``The data are encouraging that this new vaccine approach can help prevent pandemic influenza,'' said Robert B. Belshe, an immunologist and infectious disease specialist at the Saint Louis University School of Medicine, who served on an independent safety monitoring board for the study, in a statement.

No ``serious'' side effects have been reported for the Novavax vaccine study and an independent monitoring board has supported continuing the study, Novavax said in its statement. Complete safety data for the study aren't yet available, the company said.

Novavax also is conducting two preliminary studies of a vaccine for seasonal influenza, which causes more than 500,000 deaths worldwide annually. One of the studies will test the vaccine on healthy young adults and another on people age 65 and over. Results of those studies are expected in late 2008 or early 2009.

UNCLASSIFIED